AU2004225901B2

AU2004225901B2 - Multiplex screening for lysosomal storage disorders (LSDs)

Info

Publication number: AU2004225901B2
Application number: AU2004225901A
Authority: AU
Inventors: Douglas Alexander Brooks; Caroline Dean; John Joseph Hopwood; Peter John Meikle
Original assignee: Children Youth and Womens Health Service Inc
Current assignee: Children Youth and Womens Health Service Inc
Priority date: 2003-03-31
Filing date: 2004-03-31
Publication date: 2010-04-15
Anticipated expiration: 2024-03-31
Also published as: AU2004225901A1

Description

WO 2004/088322 PCT/AU2004/000403 1 MULTIPLEX SCREENING FOR LYSOSOMAL STORAGE DISORDERS (LSDs) RELATED APPLICATIONS: 5 [0001] This application claims priority to the following applications: (1) Australian Provisional Patent Application, Serial Number 2003/901451, entitled "AN IMPROVED METHOD OF SCREENING FOR LYSOSOMAL STORAGE DISORDERS," filed on March 31, 2003, having Hopwood et al., listed as inventors; (2) Australian Provisional Patent Application, Serial Number 2003/904174, entitled "MULTIPLEX SCREENING FOR 10 LSD'S," filed on August 8, 2003, having Hopwood et al., listed as inventors; (3) Australian Provisional Patent Application, Serial Number 2003/904720, entitled "MULTIPLEX SCREENING FOR LSD'S," filed on September 2, 2003, having Hopwood et al., listed as inventors. The entire content of each of the above identified applications is hereby incorporated by reference. 15 BACKGROUND: [0002] The present invention is generally related to diagnostics that determine Lysosomal Storage Disorders ("LSDs") and related diseases in a subject. More particularly, this invention pertains to compounds, reagents, and methods for identifying and quantifying the levels and ratios of multiple target antigens that are used to accurately diagnose LSD. 20 The target antigens are naturally present in biological fluids or tissues of either LSD or non LSD patients. [0003] LSDs represent a group of over 40 distinct genetic diseases that generally affect young children. Individuals that are affected with a LSD present a wide range of clinical symptoms that depend upon the specific disorder or a particular genotype involved. 25 The clinical symptoms associated with LSD's can have a devastating impact on both the child and the family of affected individuals. For example, central nervous system dysfunction, behavioral problems, and severe mental retardation are characteristic of many LSDs. Other clinical symptoms may include skeletal abnormalities, organomegaly, corneal clouding and dysmorphic features (Neufeld and Muenzer, 1995). Patients are usually born without the 30 visible features of a LSD, but early stage symptoms can quickly develop into a progressive WO 2004/088322 PCT/AU2004/000403 2 clinical concern. In severe cases, the affected children require constant medical management but still often die before adolescence. [0004] The significance of LSDs to health care becomes obvious when comparing the group incidence rate for a LSD (1:5,000 births) to the group incidence rate of other with well 5 known and intensively studied genetic disorders, such as phenylketonuria (1:14,000) and cystic fibrosis (1:2,500), wherein these figures reflect incidence rates for Caucasian populations. [0005] Once an individual begins to present the symptoms of a LSD, the actual clinical diagnosis of the disease is still a complex process. A clinical diagnosis of a LSD 10 often requires multiple visits to a range of specialists, which can take months or even years. This long process is extremely stressful on the patient and family. Fortunately, there has been considerable progress in the diagnosis of LSDs over the past 20 years. For example, the development and introduction of chromatographic-based urine screens for a specific group of LSDs called mucopolysaccharidoses ("NPS") and oligosaccharidoses has facilitated 15 screening of clinically selected patients for these disorders. Following a clinical index of suspicion for the disorders, the next stage of diagnosis involves a urine screen, wherein a "positive" urine screen is then followed by specific enzymatic analysis. Although the chromatographic-based screening methods are simple to perform, they are relatively labor intensive and often require experience to accurately interpret results. One example includes a 20 method of identifying and quantitating biochemical markers ("biomarkers") that are present in biological fluids or tissues of a patient having a MPS or related disorders comprises determining a target quantity of a target MPS biomarker oligosaccharide from a target biological sample taken from the target animal, and then comparing the target quantity to a reference quantity of a reference NPS biomarker oligosaccharide for the diagnosis, 25 characterization, monitoring, and clinical management of MPS and related disease, as described in PCT Application AU03/00731 entitled "identification of Oligosaccharides and their Use in the Diagnosis and Evaluation of Mucopolysaccharidoses and Other Related Disorders," filed on June 13, 2003 with Hopwood et al., listed as inventors (the entire content of PCT Application AU03/00731 is hereby incorporated by reference). Consequently, 30 chromatographic-based screening tests for LSDs are not used in some centers. Furthermore, WO 2004/088322 PCT/AU2004/000403 3 these chromatographic-based screens are not readily amenable to automation, which has further limited their utilization in screening strategies for newborns. [0006] The production of specific substrates and antibody capture assays has made the enzymatic analyses for LSDs more accurate. Although not wanting to be bound by theory, 5 the majority of LSDs result from a reduction in levels of a particular enzyme(s) involved in a specific LSD, and the identification of the specific enzyme(s) steady state in normal individuals will help identify the particular form of LSD in the affected individual. The ability to quickly and accurately determine the levels of the more than 40 enzymes known to be involved with LSDs will assist in the development of better and more economical 10 screening assays. Unfortunately, many of the chromatographic-based screens and enzyme assays mentioned above are time-consuming, invasive, complex, and require cultured cells, or tissue biopsies, which tends to make such assays inconvenient and expensive. As a result, testing for a LSD is often not a first line strategy for an affected child with early stage symptoms. Newborn screening for LSDs promises to provide early detection of the LSD, but 15 all newborns must be screened in order to detect the disease early. Patients having a family history of LSDs may have a justifiable reason to perform an early screen for a LSD. However, the cost of an early screen of the LSD in individuals not having a family history may not be justified economically. Therefore, it would be beneficial that any LSD screening process be capable of economically screening large numbers of newborns. 20 [0007] One common feature of LSDs is the accumulation and storage of materials within lysosomes. It is generally recognized that the accumulation and storage of material in LSD affected individuals results in an increase in the number and the size of lysosomes within a cell from approximately 1% to as much as 50% of total cellular volume. In non-affected individuals, such materials are typically degraded into degradation products within the 25 lysosome and then transported across the lysosomal membrane. Certain lysosomal proteins are present at elevated levels in the lysosomes of affected individuals (Meikle et al., 1997; Hua et al., 1998). These identified proteins are useful biomarkers for an early diagnosis of all LSDs. For example, sensitive immunoquantification assays have been developed to monitor the level of useful biomarkers such as the lysosome-associated membrane proteins 30 ("LAMPs"), saposins, and ox-glucosidase. Although the determination of either LAMP-1 or LAMP-2 levels alone in an 'at-increased-risk' group will identify up to 65% of LSD affected WO 2004/088322 PCT/AU2004/000403 4 individuals, the combination of a LAMP with one of the saposins increase identification of LSD affected individuals to approximately 85%. Therefore, a method to identify two or more biomarkers simultaneously would increase the accuracy of diagnosing a specific LSD as compared to any single assay. An automated multiplex assay that could perform a 5 simultaneous screen on each of the known LSD deficient enzymes would reduce time and cost for accurate LSD diagnosis. [0008] Multiplexing Bead Technology is built around 3 core technologies. The first is the family of fluorescently dyed microspheres having specific biomolecules bound to the surface of the microsphere. The second is a flow cytometer with 2 lasers and associated optics 10 to measure biochemical reactions that occur on the surface of the microspheres, and the third is a high-speed digital signal processor to efficiently manage the fluorescent output. This type of system has been described in, for example: United States Patents 6,449,562; 6,524,793 and United States Patent Application SN 09/956,857. United States Patent 6,449,562 ("the '562 Patent") entitled "Multiplexed Analysis of Clinical Specimens Apparatus and Method," 15 having Chandler et al. listed as inventors was issued on September 10, 2002. The '562 Patent discloses a method for the multiplexed diagnostic and genetic analysis of enzymes, DNA fragments, antibodies, and other biomolecules comprising the steps of constructing an appropriately labeled beadset, exposing the beadset to a clinical sample, and analyzing the combined sample/beadset by flow cytometry. Flow cytometric measurements are used to 20 classify, in real-time, beads within an exposed beadset and textual explanations, based on the accumulated data obtained during real-time analysis, are generated for the user. The inventive technology of the '562 Patent enables the simultaneous, and automated, detection and interpretation of multiple biomolecules or DNA sequences in real-time while also reducing the cost of performing diagnostic and genetic assays. However, the '562 Patent does not 25 describe how to utilize the technology for diagnosing LSD's. [0009] United States Patent 6,524,793 ("the '793 Patent") entitled "Multiplexed Analysis of Clinical Specimens Apparatus and Method," having Chandler et al. listed as inventors, was issued on February 25, 2003. The '793 Patent discloses a method for the multiplexed diagnostic and genetic analysis of enzymes, DNA fragments, antibodies, and 30 other biomolecules comprising the steps of constructing an appropriately labeled beadset, exposing the beadset to a clinical sample, and analyzing the combined sample/beadset by flow WO 2004/088322 PCT/AU2004/000403 5 cytometry. Flow cytometric measurements are used to classify, in real-time, beads within an exposed beadset and textual explanations, based on the accumulated data obtained during real-time analysis, are generated for the user. The '793 Patent enables the simultaneous, and automated, detection and interpretation of multiple biomolecules or DNA sequences in real 5 time while also reducing the cost of performing diagnostic and genetic assays. However, the '793 Patent does not describe how to utilize the technology for diagnosing LSD's. [0010] United States Patent Application Serial No. 09/956,857 ("the '857 Application") entitled "Multiple Reporter Read-out for Bioassays" was published on March 20, 2003. The '857 Application describes a method for detecting a plurality of reactive sites 10 on an analyte, comprising allowing reactants on an addressable microsphere and the reactive sites to react, forming reactant-reactive site pairs distinguishable by fluorescence intensity. The '857 Application also provides a method for detecting a plurality of analytes in a sample using addressable microspheres in combination with one or more reporter reagents. Also provided are a method for determining allele zygosity of a genetic locus having two alleles or 15 more alleles using microparticles, and a method for detecting a plurality of SNPs in nucleic acid molecules. The '857 Application also provides a composition comprising an addressable microsphere carrying at least two fluorescent reactants capable of forming reactant-analyte pairs distinguishable by their fluorescence intensity, and kits comprising the inventive composition and a plurality of reporter reagents. However, the '857 Application does not 20 describe how to utilize the technology for diagnosing LSD's. The entirety of each of the applications or patents listed above is hereby specifically incorporated by reference. [0011] Accordingly, there is a need for the development of a fast, accurate and economical screen for early diagnosis of LSDs, which is amenable to automation. The ability to identify specific LSD enzymes in an automated multiplex assay will have a significant 25 impact on the development of a newborn screening programs, as well as the ability to address a number of other issues associated with the early diagnosis and treatment of LSDs. The present invention provides compounds, reagents, and methods for a LSD diagnostic multiplex assay.

WO 2004/088322 PCT/AU2004/000403 6 FIGURES [0012] Figure 1 shows LAMP-1 levels in plasma from LSD individuals wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values between 1.5 and 3 box lengths 5 from the upper or lower edge of the box, and the extreme outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box; [0013] Figure 2 shows saposin C levels in plasma from LSD individuals wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values between 1.5 and 3 box lengths 10 from the upper or lower edge of the box, and the extreme outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box; [0014] Figure 3 shows a-Glucosidase in plasma from LSD affected individuals, wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values between 1.5 and 3 15 box lengths from the upper or lower edge of the box, and the extreme outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box; [0015] Figure 4 shows analysis of patient blood spots for LAMP-1 wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values between 1.5 and 3 box lengths 20 from the upper or lower edge of the box, and the extreme outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box; [0016] Figure 5 shows Analysis of patient blood spots for saposin C wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values between 1.5 and 3 box lengths from the upper 25 or lower edge of the box, and the extreme outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box; [0017] Figure 6 shows a-Glucosidase protein/activity determination in dried blood spots, wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values WO 2004/088322 PCT/AU2004/000403 7 between 1.5 and 3 box lengths from the upper or lower edge of the box, and the extreme outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box; [0018] Figure 7 shows a-Glucosidase protein distribution in neonates; 5 [0019] Figure 8 shows the newborn population distribution of LAMP-1 and saposin C [0020] Figure 9 shows target populations representing each LSD of interest analyzed; [0021] Figure 10 shows a microsphere capture sandwich immunoassay having a microsphere with two spectrally distinct fluorophores, the target LSD capture antibody and 10 the unique LSD target protein or target antigen bound to the target LSD capture antibody and a reporter molecule; [0022] Figure 11 shows a list of antibody reagents available for lysosomal proteins for utilization of LSD's screened by multiplex technology; [0023] Figure 12 shows a calibration curve for ax-glucosidase in a microsphere based 15 assay; [0024] Figure 13 shows multiplexed calibration curves in a microsphere based assay; [0025] Figure 14A and Figure 14B show calibration curves of ca-glucosidase using bead technology and measured using Bio-Plexm Protein Array system (Bio-Rad); [0026] Figure 15 shows the multiplex technology having at least a 4-plex for LSD's; 20 [0027] Figure 16 shows calibration curves for a 4-plex immune quantification of lysosomal proteins; [0028] Figure 17 shows multiplex analysis of control and MPS I plasma, wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values between 1.5 and 3 box lengths 25 from the upper or lower edge of the box, and the extreme outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box; WO 2004/088322 PCT/AU2004/000403 8 [0029] Figure 18 shows box plots of plasma concentrations of Lamp-1 (A), saposin C (B), a-glucosidase (C) and ax-iduronidase (D) from a control group and 6 different LSD wherein, the center line within the box represents the median, the top of the box is the 75th and the bottom of the box is the 2 5th percentile, error bars represent the largest and smallest 5 values that are not outliers, outliers represented by open circles, are values more than 1.5 box lengths from the 7 5 th and 2 5 th percentile and extremes represented by stars are values more than 3 box-lengths from the 7 5 th and 25th percentile. [0030] Figure 19 shows box plots of concentrations of Lamp-1 (A), saposin C (B), a glucosidase (C) and a-iduronidase (D) from dried blood spots, the samples were measured in 10 a control group, a newborn group, and a group of 3 LSD patients. [0031] Figure 20 shows target protein markers for LSD screening; [0032] Figure 21 shows the antibodies and bead regions used for the 7-plex assay; [0033] Figure 22 shows the calibration curves for each of the protein assays; [0034] Figure 23 shows the individual and average adult control protein values in the 15 7 plex assay obtained for each sample with the standard deviation, minimum and maximum of each group; [0035] Figure 24 shows the individual and average newborn protein values in the 7 plex assay for each sample with the standard deviation, minimum and maximum of each group; 20 [0036] Figure 25 shows the Pearson correlation coefficient between each pair of protein analytes; [0037] Figure 26 shows the protein concentrations of the LSD individuals compared to adult control group; [0038] Figure 27 shows the protein concentrations of the LSD individuals compared 25 to the newborn control group; [0039] Figure 28 shows the multiplex neonatal screening strategy for LSD; WO 2004/088322 PCT/AU2004/000403 9 [0040] Figure 29 shows the derivatization of oligosaccharides for MS/MS analysis; [0041] Figure 30 shows MS/MS analysis of a-mannosidosis urine (Precursor ion scan of m/z 175); [0042] Figure 31 shows retrospective analysis of HNAcS in newborn blood spots vs 5 blood spot age; [0043] Figure 32 shows retrospective analysis of HNAc-UA-HNAc-UA in newborn blood spots; [0044] Figure 33 shows a summary of retrospective analysis of newborn blood spots; [0045] Figure 34 shows protein markers for LSD screening using multiplex assays for 10 LSD.

10 SUMMARY 100461 Lysosomal Storage Disorders ("LSDs") represent a group of over 40 distinct genetic diseases that generally affect young children. Individuals that are affected with a LSD present a wide range of clinical symptoms that depend upon the specific disorder or a particular genotype involved. 5 The present invention is generally related to a screening diagnostic for LSD and related diseases. More particularly, this invention pertains to methods and compositions for identifying and quantifying target enzymes and proteins that are used to accurately diagnose a LSD. These target enzymes and proteins are naturally present in biological fluids or tissues of patients. The invention also pertains to a Multiplexing Bead Technology for simultaneous screening of specific LSD enzymes. 0 [0047] A first aspect of the current invention is a composition used for diagnosing a LSD. The composition comprises a capture antibody capable of binding a target antigen, and a microsphere having the capture antibody conjugated to the microsphere. The target antigen is a LSD associated biomolecule that comprises LAMP-1, saposin C, c-glucosidase, ca-galactosidase, glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N-acetylglucosaminidase, 5 galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase. The microsphere having the conjugated capture antibody preferably has a diameter of about 5 pm and at least a first fluorophore and a second fluorophore. The first fluorophore being spectrally distinct from the second fluorophore. The composition may further comprise a detection antibody, wherein the detection antibody is capable of 0 binding the target antigen, but is different from the capture antibody, and the detection antibody is conjugated to any detectable label known in the art (e.g. a fluorescent label). [00481 A second aspect of the current invention comprises a protein profiling method for diagnosing a pre-clinical status, or a clinical status of a LSD. The method comprises: (a) determining a target quantity of a-iduronidase or a-glucosidase from a target 25 biological sample of the target animal; (b) determining a target quantity of either LAMP-1 or saposin C from the target biological sample of the target animal; (c) assigning an adjusted target quantity by calculating a target proportion between the target quantity of a-iduronidase or a-glucosidase and the target quantity of either 30 LAMP-I or saposin C; (d) obtaining a reference quantity of a-iduronidase or a-glucosidase from a reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (e) obtaining a reference quantity of either LAMP-] or saposin C from the reference 5 biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (f) assigning an adjusted reference quantity by calculating a reference proportion between the reference quantity of a-iduronidase or a-glucosidase and the reference quantity of either LAMP-I or saposin C; (g) determining a deviation of the adjusted target quantity compared to the adjusted reference quantity; and 5 the determination of the target quantity of a-iduronidase or a-glucosidase, the reference quantity of a-iduronidase or a-glucosidase, the target quantity of either LAMP-1 or saposin C, and the reference quantity of either LAMP-1 or saposin C are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second fluorophore, wherein the capture 0 antibody is capable of binding to a-iduronidase or a-glucosidase or LAMP-I or saposin C; and a significant deviation of the adjusted target quantity compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to 5 a standard deviation calculated by a Mann-Whitney U(MWU) test. The method allows the determination of pre-clinical status or the clinical status of an LSD by comparing a deviation of the adjusted target quantity to the adjusted reference quantity. In one specific embodiment, the target biological sample and the reference biological sample of this method are selected from a cellular extract, blood, plasma, or urine. Alternatively, the second target antigen 0 and the second reference antigen comprise a biomarker indicator of cell number, organelle number, cell size, organelle size, cell volume, or organelle volume. [00491 A third aspect of the current invention comprises a protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage 25 disorder ("LSD") in a target animal comprising: (a) determining target quantities of a-iduronidase, a-glucosidase, a-galactosidase, p glucosidase, and N-acetylgalactosamine-4-sulphatase, from a target biological sample of the target animal; (b) determining a target quantity of either LAMP-I or saposin C from the target 30 biological sample of the target animal; (c) assigning a set of adjusted target quantities by calculating a target proportion between the target quantities of a-iduronidase, a-glucosidase, a-galactosidase, p-glucosidase, and N-acetylgalactosamine-4-sulphatase, and the target quantity of either LAMP-I or saposin C; 35 (d) obtaining reference quantities of a-iduronidase, a-glucosidase, a-galactosidase, p glucosidase, and N-acetylgalactosamine-4-sulphatase, from a reference biological sample from a reference animal, or group of reference animals, having a known LSD 12 pre-clinical or clinical status; (e) obtaining a reference quantity of either LAMP-] or saposin C from the reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; 5 (f) assigning a set of adjusted reference quantities by calculating a reference proportion between the reference quantities of a-iduronidase, a-glucosidase, a-galactosidase, p glucosidase, and N-acetylgalactosamine-4-sulphatase, and the reference quantity of either LAMP-I or saposin C; and (g) determining a deviation of the set of adjusted target quantities to the set of adjusted 0 reference quantities; wherein, the determination the target quantities of a-iduronidase, a-glucosidase, a galactosidase, p-glucosidase, and N-acetylgalactosamine-4-sulphatase, the target quantity of either LAMP-I or saposin C, the reference quantities of a-iduronidase, a 5 glucosidase, a-galactosidase, p-glucosidase, and N-acetylgalactosamine-4-sulphatase, and the reference quantity of either LAMP-I or saposin C are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second fluorophore, wherein the capture antibody is capable of binding to a-iduronidase, a-glucosidase, a-galactosidase, p-glucosidase, N o acetylgalactosamine-4-sulphatase, LAMP-I or saposin C; and a significant deviation of any of the adjusted target quantities compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U(MWIU) test. 25 100501 A fourth aspect of the current invention comprises a protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: (a) determining target quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N o acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, from a target biological sample of the target animal; (b) determining a target quantity of either LAMP-I or saposin C from the target biological sample of the target animal; .5 (c) assigning a set of adjusted target quantities by calculating a target proportion between the target quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, p- I2a glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, and the target quantity of either LAMP-1 or saposin C; 5 (d) obtaining reference quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, P-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3 -sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, from a reference biological sample from a reference animal, or group of reference 0 animals, having a known LSD pre-clinical or clinical status; (e) obtaining a reference quantity of either LAMP-I or saposin C from the reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (f) assigning a set of adjusted reference quantities by calculating a reference proportion 5 between the reference quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N sulphatase, N-acetylglucosaminidase, galactose-6-sulphatase, $-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N acetylgalactosamine-4-sulphatase, and the reference quantity of either LAMP-I or 0 saposin C; and (g) determining a deviation of the set of adjusted target quantities to the set of adjusted reference quantities; wherein, the determination the target quantities of a-glucosidase, a-galactosidase, !5 glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N sulphatase, N-acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N acetylgalactosamine-4-sulphatase, the target quantity of either LAMP-I or saposin C, the reference quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, p 0 glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, and the reference quantity of either LAMP-I or saposin C, are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first 5 fluorophore and a second fluorophore, wherein the capture antibody is capable of binding a-glucosidase, a-galactosidase, glucocerebrosidase, p-glucosidase, a iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N-acetylglucosaminidase, 12b galactose-6-sulphatase, P-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, N-acetylgalactosamine-4-sulphatase, LAMP-I or saposin C; and a significant deviation of any of the adjusted target quantities compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, 5 wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U (MWU) test. [0050a] A fifth aspect of the current invention comprises a protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: 10 (a) determining at least a first target biomolecule quantity from a target biological sample of the target animal; (b) determining at least a second target biomolecule quantity from the target biological sample of the target animal; (c) assigning an adjusted target quantity by calculating a target proportion between the 15 first target biomolecule quantity and the second target biomolecule quantity; (d) obtaining a first reference biomolecule quantity of a reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (e) obtaining a second reference biomolecule quantity of a reference biological sample !0 from a reference animal, or group of reference animals, having a known LSD pre clinical or clinical status; (f) assigning an adjusted reference quantity by calculating a reference proportion between the reference first reference biomolecule quantity and the second reference biomolecule quantity; 25 (g) determining a deviation of the adjusted target quantity compared to the adjusted reference quantity; wherein, the first target biomolecule is the same or equivalent to the first reference biomolecule; and 30 the second target biomolecule and the second reference biomolecule are either LAMP-I or saposin C; the determination of the first target biomolecule quantity and the second target biomolecule quantity are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second 12c fluorophore, wherein the capture antibody is capable of binding to the first target biomolecule or the second target biomolecule; and a significant deviation of the adjusted target quantity compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a 5 deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U(MWU) test; and wherein the first target biomolecule and the first reference biomolecule are each a-glucosidase and the LSD is Pompe; or the first target biomolecule and the first reference biomolecule are each a .0 galactosidase A, and the LSD is Fabry; or the first target biomolecule and the first reference biomolecule are each glucocerebriosidase or -glucosidase, and the LSD is Gaucher; or the first target biomolecule and the first reference biomolecule are each a-iduronidase and the LSD is MPS I; or 15 the first target biomolecule and the first reference biomolecule are each iduronate-2 sulphatase and the LSD is MPS II; or the first target biomolecule and the first reference biomolecule are each heparin-N sulphatase and the LSD is MPS IIIA; or the first target biomolecule and the first reference biomolecule are each a-N !0 acetylglucosaminidase and the LSD is MPS I11B; or the first target biomolecule and the first reference biomolecule are each galactose-6 sulphatase and the LSD is MLD; or the first target biomolecule and the first reference biomolecule are each sphingomyelinase and the LSD is Niemann-Pick; or 25 the first target biomolecule and the first reference biomolecule are each N acetylgalactosamine-4-sulphatase and the LSD is MPS IV. 10050b A sixth aspect of the current invention comprises a protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: 30 (a) determining a target quantity of a-iduronidase or a-glucosidase from a target biological sample of the target animal; (b) determining a target quantity of either LAMP-I or saposin C from the target biological sample of the target animal; 12d (c) assigning an adjusted target quantity by calculating a target proportion between the target quantity of a-iduronidase or a-glucosidase and the target quantity of either LAMP-] or saposin C; (d) determining a second target quantity of a-iduronidase or a-glucosidase from a second 5 target biological sample of the target animal; (e) determining a second target quantity of either LAMP-I or saposin C from the second target biological sample of the target animal; (f) assigning a second adjusted target quantity by calculating a second target proportion between the second target quantity of a-iduronidase or a-glucosidase and the second 0 target quantity of either LAMP-I or saposin C; (g) obtaining a reference quantity of a-iduronidase or a-glucosidase from a reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (h) obtaining a reference quantity of either LAMP-I or saposin C from the reference 5 biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (i) assigning an adjusted reference quantity by calculating a reference proportion between the reference quantity of a-iduronidase or a-glucosidase and the reference quantity of either LAMP-I or saposin C; 0 (j) determining (i) a deviation of the adjusted target quantity compared to the adjusted reference quantity; (ii) a second deviation of the second adjusted target quantity compared to the adjusted reference quantity; and the determination of the target quantity of a-iduronidase or ca-glucosidase, the reference quantity of a-iduronidase or a-glucosidase, the target quantity of either 25 LAMP-I or saposin C, and the reference quantity of either LAMP-I or saposin C are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second fluorophore, wherein the capture antibody is capable of binding to a-iduronidase or a-glucosidase or LAMP-] or saposin C; 30 and a significant deviation of the adjusted target quantity compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U (MWU) test; and the second target biological sample is obtained at a different time point than the target 35 biological sample and a magnitude of divergence between the deviation and the second deviation determines whether the LSD therapy will be administered, monitored, or modified.

WO 2004/088322 PCT/AU2004/000403 13 DETAILED DESCRIPTION Terms: [0051] The term "a" or "an" as used herein in the specification may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising", the 5 words "a" or "an" may mean one or more than one. As used herein "another" may mean at least a second or more. [0052] The term "animal," "subject," or "patient" as used herein may be used interchangeably and refers to any species of the animal kingdom. In preferred embodiments it refers more specifically to humans. 10 [0053] The term "biomolecule" as used herein is understood to represent the target molecule, such as a protein, an antibody, a metabolite, a DNA sequence, an RNA sequence, a biologic with activities used or measured for the purposes multiplexing and profiling of target biomolecules, or a combination thereof, for the composition and method of determining LSD, used in administering, monitoring, or modifying an LSD therapy. 15 [0054] The term "clinical status" as used herein refers to patients that are being studied or treated by physicians for a LSD. [0055] The term "comprise," or variations such as "comprises" or "comprising," as used herein may be used to imply the inclusion of a stated element or integer or group of elements or integers, but not the exclusion of any other element or integer or group of 20 elements or integers. [0056] The term "fluorophore" as used herein refers to any fluorescent compound or protein that can be used to quantify the LSD antigens. [0057] The term "normalize" as used herein refers to bringing a target, reference, or other samples into conformity with a standard, pattern, model, etc. For example, in one 25 embodiment, urine samples from LSD patients and non-LSD patients were normalized by using a 1 pnmol equivalent of creatinine from each sample.

WO 2004/088322 PCT/AU2004/000403 14 [0058] The term "phenotype" as used herein refers to the manifest characteristics of an organism collectively, including anatomical and psychological traits, that result from both its heredity and its environment. [0059] The term "preclinical status" as used herein refers to the period of a disease 5 before any of the clinical symptoms appear. [0060] The term "lysosomal storage disorder ("LSD") associated biomolecule" as used herein refers to any biomolecule that has been linked to any LSD. In preferred embodiments, a LSD associated biomolecule includes, but is not limited to: a-iduronidase, a glucosidase, saposin C, LAMP-1, LAMP-2, p-glucosidase, a-galactosidase A, iduronate-2 10 sulphatase, a-iduronidase, N-acetylgalactosamine 4-sulphatase, galactose 6-sulphatase, acid sphingomyelinase, galactocerebrosidase, arylsulphatase A, saposin B, heparan-N-sulphatase, a-N-acetylglucosaminidase, acetylCoA: glucosamine N-acetyltransferase, N acetylglucosamine 6-sulphatase, p-galactosidase, p-glucuronidase, aspartylglucosaminidase, acid lipase, p-hexosamindase A, p-hexosamindase B, GM2-acitvator, acid ceramidase, a-L 15 fucosidase, a-D-mannosidase, p-D-mannosidase, neuraminidase, phosphotransferase, phosphotransferase g-subunit, palmitoyl protein thioesterase, tripeptidyl peptidase I, cathespsin K, a-galactosidase B, or sialic acid transporter. As shown below, Table 1 indicates some enzyme deficiencies for LSDs.

WO 2004/088322 PCT/AU2004/000403 15 Table 1 Enzymes deficient in some common lysosomal storage disorders Disease Clinical Phenotype Enzyme Deficiency Australian Prevalence Gaucher disease types I / II / III Gaucher disease Glucocerebrosidase 1 in 57,000 (f-glucosidase) Cystinosis Cystine transporter 1 in 192,000 Fabry disease Fabry disease a-Galactosidase A 1 in 117,000 Glycogen storage disease II Pompe disease a-Glucosidase 1 in 146,000 Mucopolysaccharidosis type I Hurler/Scheie a-L-Iduronidase 1 in 88,000 syndrome Mucopolysaccharidosis type II Hunter syndrome Iduronate-2-sulphatase 1 in 136,000 Mucopolysaccharidosis type VI Maroteaux-Lamy N-acetylgalactosamine 4- 1 in 235,000 syndrome suiphatase Mucopdlysaccharidosis type Morquio syndrome Galadose 6-sulphatase 1 in 169,000 IVA Niemann-Pick disease types A / Niemann-Pick disease Acid sphingomyelinase 1 in 248,000 B Globoid cell leucodystrophy Krabbe disease Galadocerebrosidase 1 in 201,000 Metachromatic leucodystrophy Arylsuiphatase A 1 in 92,000 Metachromatic leucodystrophy Saposin B Mucopolysaccharidosis type Sanfilippo syndrome Heparan-N-sulphatase 1 in 114,000 IEIA Mucopolysaccharidosis type Sanfilppo syndrome a-N-Acetylglucosaminidase 1 in 211,000 Mucopolysaccharidosis type Sanfilippo syndrome AcetylCoA:N- 1 in 1,407,000 Ic acetyltransferase Mucopolysaccharidosis type Sanfilippo syndrome N-Acetylglucosamine 6- 1 in 1,056,000 IJID suiphatase Mucopolysaccharidosis type Morquio syndrome P-Galactosidase IVB Mucopolysaccharidosis type VII Sly P-Glucuronidase 1 in 2,111,000 Niemann-Pick disease type C1 Niemann-Pick disease Cholesterol trafficking 1 in 211,000 Niemann-Pick disease type C2 Niemann-Pick disease Cholesterol trafficking Aspartyiglucosamninuria Aspartylglucosaminidase 1 in 2,111,000 Cholesterol ester storage disease Wolnaan disease Acid lipase 1 in 528,000 GM1-Gangliosidosis types f-Galactosidase 1 in 384,000 Sanilipo/yndom GM2-Gangliosidosis type I Tay Sa s disease P-Hexosaminidase A 1 in 201,000 GM2-Gangliosidosis type IC Sandhoff disease a -Hexosainidase A & B 1 in 384,000 GM2-Gangliosidosis GM2-activator deficiency Farber Lipogranulomatosis Farber disease Acid ceramidase Fucosidosis a-L-Fucosidase > 1 in 2,000,000 Galactosialidosis types I / II Protective protein M-Mannosidosis types I / II a-D-Mannosidase 1 in 1,056,000 G-Mannosidosis td-D-Mannosidase Mucolipidosis type I Sialidosis types I / Neuraminidase Mucoiapidosis types I / In I-cell disease; Phosphotransferase 1 in 325,000 Mucolipidosis type IIIC pseudo-Hurler Phosphotransferase g-subunit polydystrophy Mucolipidosis type IV Unknown Multiple sulphatase deficiency Multiple sulphatases 1 in 1,407,000 Neuronal Ceroid Batten disease Pal-toyl protein thioesterase WO 2004/088322 PCT/AU2004/000403 16 Lipofuscinosis, CLN1 Neuronal Ceroid Batten disease Tripeptidyl peptidase I Lipofuscinosis, CLN2 Neuronal Ceroid Vogt-Spielmeyer Protein function not known Lipofuscinosis, CLN3 disease Neuronal Ceroid Batten disease Protein function not known Lipofuscinosis, CLN5 Neuronal Ceroid Northern Epilepsy Protein function not known Lipofuscinosis, CLN8 Pycnodysostosis Cathepsin K Sialic acid storage disease Schindler disease a-Galactosidase B Sialic acid storage disease Sialuria; salla disease Sialic acid transporter 1 in 528,000 Prevalence figures quoted from Miekle et al., JAMA 281:249-254 (1999). Prevalence and ratio of lysosomal storage disorders may vary from country to country WO 2004/088322 PCT/AU2004/000403 17 [0061] The term "reference quantity" as used herein refers to a known, normalized amount of a LSD biomarker in a biological fluid. The reference quantity is determined from an animal, or group of animals having a defined clinical status, preclinical status, or 5 phenotype of a LSD disease. The reference quantity may refer to a table compiled from various animals or groups of animals having correlations between relative amounts of LSD biomarkers in a biological fluid, and a known clinical status, preclinical status, or phenotype. LYSOSOMAL STORAGE DISORDERS [0062] The LSD's represent a group of over 40 distinct genetic diseases that generally 10 affect young children. Patients are usually born without the visible features of a LSD, but early stage symptoms can quickly develop into a progressive clinical concern. Although some effective LSD therapies have been developed, it is paramount that therapy be started as soon as the LSD has been diagnosed. Unfortunately, a clinical diagnosis of a LSD often requires multiple visits to a range of specialists requiring time-consuming, invasive, complex, 15 inconvenient, and expensive assays. The current process for an accurate diagnosis of LSD for a patient not having a family history of LSD can take months to years, which is unacceptable when effective LSD therapies are needed earlier. [0063] It is generally recognized that the accumulation of storage materials in the lysosomes of LSD affected individuals will increase from approximately 1% to as much as 20 50% of the total cellular volume. Certain lysosomal proteins are present at altered levels in the LSD affected individuals (Meilde et al., 1997; Hua et al., 1998), as indicated in Figures 1 6. The values for the individual immunoassays in plasma samples were determined as follows arid shown in Figures 1-6. Unless stated otherwise all regents were of analytical grade and were obtained from Sigma Chemical Company, MO USA. Preparation of recombinant 25 proteins, antibodies and calibration standards for Lamp-1 and saposin C. Recombinant Lamp 1 (minus tail) was isolated from CHO-KI cells as detailed in Isaac et al [Isaac EL, Karageorgous LE, Brooks DA, Hopwood JJ and Meikle PJ. Experimental Cell Research 2000, 254: 204-209]. Recombinant Saposin C was a gift from Dr GA Grabowski and was prepared by the method of Qi and Grabowski [Qi TL and Grabowski GA J Biol Chem 1994, 30 269: 16746-16753].

WO 2004/088322 PCT/AU2004/000403 18 [0064] The anti Lamp-i monoclonal antibody (BB6) was generated using intact Lamp-1 protein by the method of Carlsson and Fukada [Carlsson SR and Fukada M JBC (1989) 264(34): 20526-20531] and 7B2 (anti Saposin C) monoclonal antibody was produced using the recombinant protein by the method described in [Zola H and Brooks D. Techniques 5 for the production and characterization of monoclonal hybridoma antibodies. In: Hurrell JGR, ed. Monoclonal hybridoma antibodies: techniques and applications. Boca Raton, FL: CRC Press, 1982:1-57]. Polyclonal antibodies were generated for both Lamp-i and Saposin C by immunizing separate rabbits with 200gg of each recombinant protein per inoculation (four inoculations in total) based upon the method of Leonova et al, 1996, [JBC 271:17312 10 20]. All antibodies were purified using 5ml Hitrap TM Protein G affinity column (Pharmacia, Uppsala, Sweden). The polyclonal antibodies were affinity purified further by column chromatography using their respective recombinant proteins coupled to Affi-Gel* 10 Gel (Bio-Rad #153-6046, CA, USA) according to manufacturers instructions. [0065] Blood spot calibrators containing final concentrations of 2000, 1000, 500, 250, 15 62.5 and 0 pg/L for Lamp-i and saposin C were prepared as detailed in Umapathysivam et al [Umapathysivam K, Whittle AM, Ranieri E, Bindloss C, Ravenscroft EM, van Diggelen OP, Hopwood JJ and Meikle PJ Clin Chem 46(9): 1318-1325 2000]. Two blood spot controls containing low (Lamp-1 400gg/L; saposin 200 g[L) and high (Lamp-1 800gg/L; saposin C 500gg[L) protein concentrations were similarly prepared. 20 [0066] Quantification of Lamp-1 and Saposin C in dried blood spots containing EDTA. Lamp-1 and Saposin C were measured in dried blood spots using one step three tier, time-delayed fluorescence immunoassays. Microtiter plates (Labsytems, Helsinki, Finland #95029180) were coated with either BB6 or 7B2 at a concentration of 5 gg/L in 0.1mol/l NaHCO3, pH 8.3 and incubated covered for approximately 16hrs at 4*C. Plates were washed 25 twice with wash buffer (0.25mol/1 NaCl, 0.02mol/l Tris containing 0.005% Tween 20 (BDH, Poole, England) and 0.002% Thiomerosal, pH7.8) Non-specific binding sites on the plates were blocked by the addition of 10O 1 of 0.25M NaCl, 0.02M Tris containing 0.5% skim milk powder (Diploma, Bonlac Foods, Victoria, Australia), pH 7.8, per well. After a two hour incubation at room temperature, the microtiter plates were washed twice with 0.25M NaCl, 30 0.02M Tris pH 7.8 and tapped dry before being lyophilized and stored desiccated at 4*C prior to use.

WO 2004/088322 PCT/AU2004/000403 19 [0067] Standard calibrators, controls and patient dried blood spots were placed in duplicate into the coated microtiter wells with 200pl of either polyclonal antibody diluted in assay buffer (0.15mol/l NaCl, 0.05mol/L Tris, 20pmol/L Diethylene triamine-penta-acetic acid, containing 0.01% Tween 40, 0.5% bovine serum albumin (A-9647), 0.05% bovine y 5 globulin (G-7516), and 0.05% sodium azide, pH 7.8). The antibodies were used at a final concentration of 200gg/L and 400gg/L for the anti-Lamp-1 and anti saposin C polyclonal respectively. The plates were covered and incubated at room temperature for one hour with shaking, then placed overnight at 4*C, followed by an hour incubation with shaking at room temperature. The blood spots were removed by suction and the plates washed six times with 10 wash buffer. After dilution in assay buffer to final concentration of 0.1 gg/ml, 10Opl of anti rabbit europium labeled antibody (Wallac, Finland #AD0105), was added to every well and incubated for one hour at room temperature with shaking. After washing the plates a final six times with wash buffer, 2001 of DELFIA* Enhancement solution (Wallac, Finland) was added per well and the plates incubated at room temperature for ten minutes with shaking. 15 Fluorescence was measured on a DELFIA* 1234 Research Fluorometer (Wallac, Finland). The concentrations of Lamp-1 and Saposin C in the blood spots were calculated using spline fit curves generated by Multicalc Data Analysis software (version 2.4 Wallac, Finland). [0068] Figure 1 shows the LAMP-1 levels in plasma from LSD individuals that are indicated by the box length being the interquartile range that covers 25th to 75th percentile. 20 Figure 2 shows saposin C levels in plasma from LSD individuals wherein the box length is the inter-quartile range that covers 25th to 75th percentile. Figure 3 shows a-Glucosidase in plasma from LSD affected individuals, wherein the box length is the inter-quartile range that covers 25th to 75th percentile. [0069] Target enzymes can also be detected by individual immunoassays in dried 25 blood spots, as indicated in Figure 4, Figure 5, and Figure 6. For example, Figure 4 shows analysis of patient blood spots for LAMP-1, wherein the box length is the inter-quartile range that covers 25th to 75th percentile. Figure 5 shows Analysis of patient blood spots for saposin C wherein the box length is the inter-quartile range that covers 25th to 75th percentile. Figure 6 shows a-Glucosidase protein/activity determination in dried blood spots, wherein the box 30 length is the inter-quartile range that covers 25th to 75th percentile. Figure 7 shows a Glucosidase protein distribution in neonates. Figure 8 shows the newborn population WO 2004/088322 PCT/AU2004/000403 20 distribution of LAMP-1 and saposin C, and Figure 9 shows target populations representing each LSD of interest analyzed. [0070] Although certain lysosomal target proteins are present at altered levels in the affected individuals, the current individual screening assays may be inaccurate due to 5 variations among individual samples. For example, a given sample is assumed to contain an average number of lysosomes or white blood cells ("WBC"), however variations in these values between individual samples are not typically considered. Thus, variations in an individual having a deficiency in a particular LSD biomolecule (e.g. lysosomal target protein), but also having an unusually high WBC count or high numbers of lysosomes in the test 10 sample may return an assay result that is consistent for individuals that do not have a LSD. Consequently, if WBC or high numbers of lysosomes were controlled in the sample preparation a large inaccuracy could be avoided, and a proper diagnosis could be made during the first round of LSD screening. [0071] Determining the quantities of multiple target enzymes increases the accuracy 15 of diagnosing a specific LSD as compared to any single assay. For example, using immunoquantification assays directed toward identifying the levels of the lysosome associated membrane proteins ("LAMPs"), such as LAMP-1 or LAMP-2, in an "at-increased risk" group will identify up to 65% of LSD affected individuals. However, the combination of LAMP's with one of the saposins increases identification of LSD affected individuals to 20 approximately 85%. Therefore, a method to identify two or more biomarkers simultaneously would increase the accuracy of LSD diagnosis and reduce the time and cost for each assay. A Multiplexing Bead Technology is used to simultaneously detect specific at least 2 LSD target antigens is described below or in Table 1. EXAMPLE 1 25 [0072] Multiplexing Bead Technology and Target LSD Proteins. The Multiplexing Bead Technology is built around 3 core technologies. The first is the family of fluorescently dyed microspheres having bound biomolecules. The second is a flow cytometer with 2 lasers and associated optics to measure biochemical reactions that occur on the surface of the microspheres, and the third is a high-speed digital signal processor to efficiently 30 manage the fluorescent output. Bio-Rad (Hercules, CA), provides a commercially available WO 2004/088322 PCT/AU2004/000403 21 protein array system called the "Bio-Plex"". The Bio-PlexM protein array system includes fluorescently dyed microspheres, a flow cytometer with 2 lasers and associated optics, and a high-speed digital signal processor. However, neither the Bio-PlexM protein array system nor any other commercially available systems include any specific biomolecules, methods, 5 compounds, or reagents needed for the simultaneous screening of specific LSD enzymes. [0073] The Bio-Plexm protein array system uses multiplexing technology to enable the simultaneous quantitation of up to 100 different analytes. This technology uses polystyrene microspheres internally dyed with differing ratios of 2 spectrally distinct fluorophores. Each fluorophore can have any of 10 possible levels of fluorescent intensity, 10 thereby creating a family of 100 spectrally distinct bead sets. In a preferred embodiment, the dyed microspheres are conjugated with monoclonal antibodies specific for a target LSD protein or peptide thereof. Although not wanting to be bound by theory, each of the 100 spectrally distinct bead sets can contain a capture antibody specific for a unique LSD target protein. In a multiplexed Bio-PlexTm assay, LSD antibody-conjugated beads are allowed to 15 react with the sample and a secondary LSD .antibody, or a detection LSD antibody in a microtiter plate well to form a capture sandwich immunoassay. Figure 10 shows a drawing of a complete microsphere capture sandwich immunoassay having a polystyrene microsphere (110) with 2 spectrally distinct fluorophores; the target LSD capture antibody (120) bound to the microsphere; a unique LSD target protein or target antigen (130) bound to the target LSD 20 capture antibody; a detection LSD antibody (140); and a detection molecule (150). Once the complete microsphere capture sandwich immunoassay has formed in solution, the immunoassay solution is then drawn into the Bio-Plexm array reader, which illuminates and reads the sample. Although not wanting to be bound by theory, there are many enzyme deficiencies specific for a particular LSD, and some of these enzymes are shown in Table 1. 25 Specific capture antibodies, and detection antibodies for the target compounds are available for specific LSD's, as shown in Figure 11. Additional capture antibodies and detections antibodies include: P-glucosidase; a-galactosidase A; iduronate-2-sulphatase; a-iduronidase; N-acetylgalactosamine 4-sulphatase; galactose 6-sulphatase; acid sphingomyelinase; galactocerebrosidase; arylsulphatase A; saposin B; heparan-N-sulphatase; a-N 30 acetylglucosaminidase; acetylCoA: glucosamine N-acetyltransferase; N-acetylglucosamine 6 sulphatase; p-galactosidase; 0-glucuronidase; aspartylglucosaminidase; acid lipase; p hexosamindase A; p-hexosamindase B; GM2-acitvator; acid ceramidase; a-L-fucosidase; a- WO 2004/088322 PCT/AU2004/000403 22 D-mannosidase; p-D-mannosidase; neuraminidase; phosphotransferase; phosphotransferase g subunit; palmitoyl protein thioesterase; tripeptidyl peptidase I; cathespsin K; a-galactosidase B; sialic acid transporter. [0074] When a red diode "classification" laser (635 nm) in the Bio-PlexM array 5 reader illuminates a dyed bead, the bead's fluorescent signature identifies it as a member of one of the 100 possible bead sets. Bio-Plexm Manager software correlates each bead set to the assay reagent that has been coupled to it (for example, a first LSD capture antibody coupled to bead set #22, and a second LSD capture antibody coupled to bead set #42). In this way the Bio-Plexm protein array system can distinguish between the different assays 10 combined within a single microtiter well. A green "reporter" laser (532 nm) in the array reader simultaneously excites a third fluorescent dye (phycoerythrin, "PE") bound to the detection LSD antibody in the assay. Although not wanting to be bound by theory, the amount of green fluorescence is proportional to the amount of target analyte captured in the immunoassay. Extrapolating the captured amount of target analyte to a standard curve allows 15 quantitation of each LSD analyte in the sample. The digital signal processing algorithms provide simultaneous real-time data acquisition of classification and reporter signal output from thousands of beads per second, supporting up to 100 x 96 = 9,600 analyte measurements from each 96-well plate. EXAMPLE 2 20 [0075] Designing and Producing LSD Target Microspheres. The BioPlex Protein Array System was used as one embodiment to demonstrate the type and nature of the reagents necessary for a LSD multiplex diagnostic assay. Four target proteins (e.g. LAMP-1, o iduronidase, a-glucosidase, and saposin C ) were used to design target capture microspheres and target reporter antibodies. 25 [0076] The monoclonal capture antibody for LAMP-1 was BB6 developed and provided by Sven Carlsson (Carlsson et al., 1989). The monoclonal reporter antibody for a glucosidase (43D1) was obtained from Pharming, Inc. and has been described (Fransen et al., 1988). The polyclonal reporter antibody for LAMP-1, the rabbit polyclonal reporter antibody for saposin C, the sheep polyclonal capture antibody for a-glucosidase, and the monoclonal 30 capture antibody ("7B2") for saposin C were prepared within the Lysosomal Diseases WO 2004/088322 PCT/AU2004/000403 23 Research Unit at the WCH in Adelaide, Australia using standard techniques, known in the art, and briefly described below. The availability and production of specific monoclonal and polyclonal antibodies are know to one of ordinary skill in the art. Production of the specific antibodies uses in the current examples are given below: 5 [0077] Polyclonal Antibodies. Sheep polyclonal antibody was produced against recombinant proteins. A sheep was injected sub-cutaneously with 2mg of protein in 1 mL of an emulsion of phosphate buffered saline (pH 7.4) and complete Freunds adjuvant, followed by four booster injections (2mg each) with incomplete Freunds adjuvant, each three weeks apart. One week after the last injection the sheep was bled out and serum collected. Rabbit 10 polyclonal antibody was produced in the same manner, except 0.2-1.0 mg of protein was used per immunisation. Sheep polyclonal antibody was purified on a 5 mL Hitrap M Protein G affinity column (Pharmacia Biotech, Uppsala, Sweden) followed by an affinity column prepared from the recombinant protein used for the immunisation. Recombinant protein affinity columns were prepared by coupling 5 mg of the recombinant protein to 2.5 mL of 15 Affi-gel 10 (Bio-Rad, Hercules, CA, USA) as per manufacturer's instructions. [0078] Briefly, 5 mL of sheep serum was diluted with 5 mL of phosphate buffered saline (pH 7.4) and centrifuged (2200g, 10 min, 4*C). The centrifuged serum was passed through a 0.2 pm filter, and then loaded on to the Protein G column at a flow rate of 0.5 mL/min. The column was washed with phosphate buffered saline, pH 7.4 and the antibody 20 eluted with 0.1 mol/L H 3

PO

4 /NaH 2

PO

4 , pH 2.5 and immediately neutralised by adding 1.0 mol/L Na 2

HPO

4

(

1

/

1 0 h vol). The protein content was estimated by absorbance at 280nm (absorbance = 1.4 for 1.0 g/L of protein). The eluate was diluted four fold and then loaded on to the appropriate recombinant protein affinity column at the same flow rate. The column was washed and eluted as described for the Protein G column. 25 [0079] Monoclonal Antibodies. Monoclonal antibodies were produced in Balb/C mice using standard immunisation protocols (Harlow et al., 1988). Mice were inimunised with recombinant enzyme using established protocols. Plasma cells from these immunised mice were fused with P3.653 myeloma cells (Zola et al., 1982) and the resulting hybridoma cell lines screened for antibodies against the recombinant protein by direct ELISA (Harlow et 30 - al., 1988). Monoclonal antibodies were purified from cell culture supernatants by WO 2004/088322 PCT/AU2004/000403 24 ammonium sulfate precipitation followed by affinity purification on HitrapI"" Protein G affinity column (Pharmacia Biotech, Uppsala, Sweden). [0080] Coupling Antibodies to Microspheres. The target capture antibodies were coupled to Bio-Rad carboxylated ("COOH") beads as follows: anti-LAMP-1 to bead #(17), 5 anti-saposin C to bead #(19), and anti-a-glucosidase to bead #(21). The coupling of the target capture antibodies to the polystyrene microspheres was performed using the BioRad bead coupling kit (Catalog number 171-406001, BioRad, Hercules, CA). The Bio-Plex T M amine coupling kit includes 4 ml bead wash buffer, 85 ml bead activation buffer, 135 ml PBS, pH 7.4, 10 ml blocking buffer, 25 ml storage buffer, 105 ml staining buffer, 40 coupling reaction 10 tubes. The Bio-PlexTM amine coupling kit provides the buffers necessary to covalently couple 6-150 kD proteins to 5.5 ym dyed carboxylated polystyrene beads in under 5 hr. The covalent couple of the target capture antibody to the carboxylated polystyrene bead is achieved via carbodiimide reactions involving the protein primary amino groups and the carboxyl functional groups bound on the surface of polystyrene beads. The covalent 15 attachment is permanent, leaving no unbound protein after cleanup, even after months of storage. The protein-coupled beads can then be used in multiplex protein-protein binding studies or in the development of multiplex assays that can be analyzed with the Bio-Plex TM protein array system. The bead yield per coupling reaction is approximately 80%, or enough protein-coupled beads for two 96-well microtiter plates using 5,000 beads per well. 20 [0081] Once the coupling reaction was completed, the target capture antibody-coupled beads were enumerated and the efficiency' of the protein coupling reaction was validated, according to the manufacturer's protocol with modifications. In this procedure, the protein coupled beads were reacted with a phycoerythrin ("PE")-labeled antibody that binds to the coupled protein, which was then analyzed using the Bio-PlexTM protein array system. This 25 procedure was performed by reacting the beads with a PE-labeled antibody. Alternatively, a reaction using a biotinylated antibody followed by streptavidin-PE may be used. Although not wanting to be bound by theory, the intensity of the fluorescent signal of this reaction is directly proportional to the amount of protein on the surface of the beads. A successful coupling typically yields a mean fluorescent intensity ("MFI") signal that is greater than 30 2,000. The protein coupling validation procedure provided a rapid relative assessment of the amount of protein coupled to the beads, but could not verify the functionality of the protein.

WO 2004/088322 PCT/AU2004/000403 25 [0082] Coupling of the phycoerythrin reporter molecule to the detection antibodies in the LAMP-1, saposin C and a-glucosidase assays was achieved using the Molecular Probes (Eugene, Oregon, USA) Protein-Protein Coupling Kit, as per manufacturer's instructions with modifications. There are several published methods known in the art for preparation of 5 phycobiliprotein conjugates with antibodies and other proteins. Generally, the coupling chemistry used to crosslink a phycobiliprotein to another protein includes: (a) treating the antibody or other protein with a succinimidyl ester maleimide derivative at pH 7.5, which converts some lysine residues of the antibody to thiol-reactive maleimides; (b) preparing a thiolated phycobiliprotein by reducing the appropriate SPDP-modified phycobiliprotein with 10 dithiothreitol ("DTT") or with tris-(2-carboxyethyl)phosphine ("TCEP"); (c) mixing the above two dialyzed protein conjugates to yield a stable thioether crosslink; and (d) chromatographically separating the phycobiliprotein conjugates from the unreacted proteins. [0083] A calibration curve was generated using liquid calibrator proteins in a microsphere based assay using calibrator protein capture antibodies and bead sets #17, #19 15 and #21 respectively (BioRad, Hercules, CA, USA). Figure 12 shows a calibration curve for a single assay for a-glucosidase. The detection capability for the amount of calibrator protein present in each well reaction was linear in the range of 0 to 4 ng/well of the assay. The MFI was the average of the total fluorescence detected for the beads in the defined bead region. Calibration curves were also established, using liquid calibrators, for LAMP-1 (open square), 20 saposin C (open circle), and a-glucosidase (open triangle), as shown in Figure 13. Increased MFI for the a-glucosidase protein, when compared to Figure 12, is the result of improvements in the capture antibody labeling of the microspheres and the phycoerythrin reporter labeled antibodies. [0084] Figure 13 also indicates that the detection capability for a multiplex assay of 25 three calibrators was linear from 0 to 2 ng/well of the assay. The sensitivity of the microsphere assay system was also demonstrated with the target capture sheep polyclonal antibody for a-glucosidase and bead set (#19) using a biotinylated reporter antibody with streptavidin-phycoerythrin conjugate (Molecular Probes #S-866). As shown in Figure 14, a glucosidase was detectable down to a level of 10 pg /well using this assay. Figure 14A shows 30 the calibration curve in the range 0-2.5 ng/well, and Figure 14B shows the same calibration curve expanded in the range 0-0.156 ng/well.

WO 2004/088322 PCT/AU2004/000403 26 EXAMPLE 3 [0085] Four-plex Assay for the Determination of LAMP-1, a-Iduronidase, a Glucosidase and Saposin C. A high sensitivity, four-plex assay for target antigens LAMP-1, ca-iduronidase, a-glucosidase, and saposin C was developed using the microsphere 5 technology based upon Luminex LABMAPTM technology. As a general illustration, Figure 15 shows a drawing of a microsphere collection of capture sandwich immunoassays for the 4 plex having: 4 spectrally distinct polystyrene microsphere (510-513); 4 target LSD capture antibody (520-523) bound to the microsphere; 4 unique LSD target proteins or target antigens and representing saposin, LAMP-1, a-iduronidase and a-gulucosidase (530-533) bound to the 10 corresponding target LSD capture antibody; 4 unique detection LSD antibody (540-543); and a detection molecule (550). [0086] Specific Target Capture Microspheres and Target Reporter Antibodies. Specific target capture microspheres and target reporter antibodies were produced using antibodies directed against four specific target proteins (e.g. LAMP-1, a-iduronidase, a 15 glucosidase, and saposin C), as described above. The sheep anti-a-iduronidaseO and anti-a glucosidase polyclonal antibodies were initially purified by ammonium sulphate precipitation. The ammonium sulphate precipitation purified antibodies were further purified using a protein G affinity purification (Amersham Pharmacia 5ml #17-0404-01). The protein G affinity purified antibodies were finally purified using an Hi trap NHS-activated HP column 20 (Amersham Pharmacia 5ml #17-0717-01) coupled with either a ax-iduronidase or a glucosidase protein. The antibodies for anti-LAMP-1, anti-ax-iduronidase, anti-a-glucosidase, and anti-saposin C were purified from hybridoma supernatant using protein G affinity purification according to manufacturer's specifications (Amersham Pharmacia 5ml #17-0404 01). 25 [0087] Specific target capture microspheres and target reporter antibodies were produced using antibodies directed against four specific target proteins (e.g. LAMP-1, a iduronidase, a-glucosidase, and saposin C). Specific target capture microspheres and target reporter antibodies were produced using antibodies directed against four specific target proteins (e.g. LAMP-1, ax-iduronidase, a-glucosidase, and saposin C). The capture 30 antibodies were coupled to microsphere beads by a 2-step carbodiimide reaction according to WO 2004/088322 PCT/AU2004/000403 27 manufacturers instructions (Bio-Rad, Amine coupling kit 171-406001). For example, sheep anti-a-iduronidase DandD, anti-c-glucosidase polyclonal antibodies and anti-saposin C monoclonal antibody (7B2) were coupled to dyed polystyrene beads using the antibody protein amino group via carbodiimide chemistry according to manufacturer's instructions at a 5 concentration of 9gg of IgG to 1.4x10 6 beads. [0088] One with ordinary skill in the art is aware of the several published methods known for efficiently biotinylating antibodies and other proteins. For example, the purified anti-LAMP-1, anti-a-iduronidase (IdiA), anti-a.-glucosidase (43D1), and anti-saposin C (S13C1) monoclonal antibodies were biotinylated using manufacturer's instructions for a 10 FluoReporter@ Biotin-XX Protein labeling kit F-2610 purchased from Molecular Probes (Eugene, OR). Generally, the FluoReporter@ Biotin-XX Protein Labeling Kit contains a biotin-XX succinimidyl ester, which reacts with primary amines of proteins or other biomolecules to form stable biotin conjugates. The long spacer between the biotin and the re active group in biotin-XX succinimidyl ester enhances the ability of the conjugated biotin to 15 interact with the relatively deep biotin-binding sites of avidin and streptavidin. The biotinylated protein was purified from the excess biotin using a gel filtration column. The degree of biotinylation was determined using an avidin-HABA complex and a control biotinylated goat IgG. [0089] Development of Four-plex Assays. LSD target antigen capture microspheres 20 were diluted in PBS containing 1% BSA (assay buffer). The diluted LSD target antigen capture microspheres were then added to stock beads in a 96 well filtration plate (Millipore #MABVS1210), wherein the diluted LSD target antigen capture microspheres and stock beads had a total volume of 1W per well. Each microwell containing the beads was then washed 3 times with PBS containing 0.05% Tween 20 (wash buffer) under vacuum using a 25 manifold (Millipore #MAVM0960R). Standard solutions containing LAMP-1, ac iduronidase, a-glucosidase, and saposin C protein (50gl) were added in serial 2-fold dilutions in assay buffer, as indicated. Standards were generated by using the recombinant form of each specific target protein. Biotinylated antibodies (50p) were added to each well, wherein the final concentration of each antibody was 16ng/well in assay buffer. The plate was 30 covered and incubated for 2 hours at room temperature with shaking. The wells were washed, incubated with Streptavidin R-phycoerythrin conjugate (Molecular Probes # S-866) WO 2004/088322 PCT/AU2004/000403 28 (50ng/well) in assay buffer for 10 minutes at room temperature with shaking. After a final wash, 125pl of assay buffer was added per well and the plate shaken for 5 minutes at room temperature. Fluorescence was measured using the Bio-Plexm Protein Array system in combination with the Bio-Plex"M software version 2.0 (Bio-Rad, Hercules, CA). Figure 16 5 shows the resulting calibration curves for LAMP-i (solid square), a-iduronidase (open circle), -glucosidase (open square), and saposin C (open triangle) of the four-plex assay. [0090] Samples. Plasma and blood samples were collected from infants, children and adults. Although plasma samples and dried blood spots were used as example samples, other suitable sample types are also embodied for this invention (e.g. amniotic fluid, cellular 10 extract, urine, etc.) The plasma and blood spot samples used to demonstrate the four-plex were obtained from the National Referral Laboratory and Neonatal Screening Laboratory Women's and Children's Hospital (Adelaide, Australia) and research laboratories at the Lysosomal Disease Research Unit (Adelaide, Australia). Blood collection and blood spotting techniques are well established, and known by one with ordinary skill in the art. 15 [0091] The bead assays were performed in 96 well filtration plates (Millipore MAV BVS12) and protected from light. Although 96 well filtration plates were utilized, one with ordinary skill in the art understand that other types of sample holders can be used without diverting the scope and spirit of the invention. Plasma samples were diluted in PBS containing 1% BSA (Sigma A-9647) pH 7.2 (assay buffer) at a final concentration of 20 3pl/well. Samples derived from 3mm dried blood spots were pre-eluted overnight at 4"C in 100pl of assay buffer in 96 well low protein binding plates (Greiner 655101), wherein 50W1 of each eluted sample was then transferred to a filtration plate. Sample assays and standard assays were performed in duplicate with the exception of the newborn sample blood spots, wherein only a single sample for each newborn was measured. 25 [0092] Following sample preparation, the capture antibody beads were prepared for the multiplex assay. Each individual multiplex assay contained a mixture of capture antibody beads for each of the LAMP-1, a-iduronidase, a-glucosidase, and saposin C capture antibody beads describe above. About 5,000 capture antibodies beads were placed in each sample well of a pre-wetted filtration plate. The mixtures of capture antibody beads were washed 3 times 30 under vacuum in the filtration plate using a wash buffer (PBS, 0.05% Tween 20, pH 7.2), WO 2004/088322 PCT/AU2004/000403 29 forming a washed/capture bead mixture. Diluted mixed standards or samples prepared as described above were added to the microtiter wells containing the washed/capture bead mixture forming an antigen/bead-set mixture. A mixture of the four biotinylated reporter antibodies (i.e. LAMP-1, a-iduronidase, a-glucosidase, and saposin C) was added to the 5 antigen/bead-set mixture completing assay components. [0093] The plates were sealed and incubated for about 1 hour at room temperature with shaking, then placed at 4'C overnight under static conditions. The plates were then incubated at room temperature with shaking for about 1 hour. It will be apparent to one skilled in the art of antibody hybridization that incubation conditions can be modified without 10 altering the scope and spirit of the invention. Following incubation, the plates were washed 3 times with wash buffer (PBS, 0.05% Tween 20, pH 7.2) under vacuum. Streptavidin conjugated to phycoerythrin (Molecular Probes S-866) was added to the wells and the plates were incubated at room temperature for 10 minutes. The plates were placed in a Bio-Plex suspension array system (Bio-Rad) and data was collected using Bio-Plex" Manager 15 software version 3.0 software and counting 100 beads/region. Analysis of the data was determined using a Mann-Whitney U tests (MWU) and box plots using the SPSS statistical package Version 10.0 (SPSS Inc. Chicago, IL, USA). Percentile cut offs were generated using a standard computer spreadsheet. [0094] Plasma Samples. The concentrations of LAMP-1, aX-iduronidase, a 20 glucosidase, and saposin C in plasma samples, as determined by the four-plex assay are shown in Figure 17 and Figure 18. Briefly, Figure 17 shows multiplex analysis of control and MPS I plasma, wherein the box length is the interquartile range that covers 25th to 75th percentile, the outliers are represented by (circles) each of these cases represent values between 1.5 and 3 box lengths from the upper or lower edge of the box, and the extreme 25 outlier (stars) are cases with values more than 3 box lengths from the upper or lower edge of the box. Figure 18 shows box plots of plasma concentrations of LAMP-1 (A), saposin C (B), a-glucosidase (C) and a-iduronidase (D) from a control group and 6 different LSD. The center line within the box represents the median. The top of the box is the 7 5 th and the bottom of the box is the 2 5 th percentile. Error bars represent the largest and smallest values 30 that are not outliers. Outliers represented by open circles and are considered values that are WO 2004/088322 PCT/AU2004/000403 30 more than 1.5 box lengths from the 7 5th and 2 5 th percentile. The extremes are represented by stars having values more than 3 box-lengths from the 7 5 th and 2 5 th percentile. [0095] Plasma LAMP-1 concentrations (Figure 18 A) were significantly elevated above controls for the LSD samples measured (MWU Test p<0.05). However saposin C 5 (Figure 18 B) was only elevated in the Gaucher plasma (MWU Test p<0.05). Plasma a iduronidase levels (Figure 18 D) were significantly decreased in lysosomal diseases tested with respect to controls (MWU Test p<0.05), except for MPS IIIA. MIPS I plasma is normally expected to have negligible if not zero a-iduronidase levels, however, one of the MPS I plasmas has an exceptionally high level of ax-iduronidase, which, although not wanting 10 to be bound by theory, probably result from mistargeting of the protein into circulation. From a screening point of view this patients plasma would be flagged for further investigation. Pompe plasma was the only disease group with significantly lower (MWU Test p<0.05) a glucosidase levels (Figure 18 C) when compared to control samples. [0096] Although not wanting to be bound by theory, the pattern of LAMP-1 elevation 15 in the 3 disorders as compared to controls observed in the plasma samples was not as apparent in a direct comparison of the target proteins in the sample blood spots (Figure 19 A) (e.g. none of the disorders had elevated LAMP-1). Similarly no disorder was elevated for saposin C (Figure 19 B). Although not wanting to be bound by theory, there is an extremely broad range of these four markers in newborns when compared to a tighter range of the same 4 20 markers in blood spots from older control individuals (i.e. age range 6 months to 47 years). The broad range of absolute levels of the marker protein in infants hinders a defined standard of "elevated" levels of Lamp-1 and saposin C in newborns. Additionally, there was no detectable a-iduronidase and negligible a-glucosidase protein for MPS I and Pompe disease respectively (Figure 19 C and Figure 19 D) as compared to the control group in blood spots 25 (MWU Test p<0.001). Some of the newborn control a-iduronidase levels appear to overlap with the zero levels found in MPS I samples but the lowest level for a-iduronidase in newborns was 0.243ug/L. In contrast to absolute marker measurements, the multiplex allows each protein to be compared using ratios. For example, there was one four mohth old Pompe patient who had a-glucosidase blood spots levels in the lower range of the control group 30 (Figure 19 C), this patient would have been missed in a typical screening program if the WO 2004/088322 PCT/AU2004/000403 31 determined cut-offs used only absolute protein levels. However, using the ratios with the multiplex data, ax-glucosidase can be compared against either saposin C (e.g. ratio of 0.271) or LAMP-1 (e.g. ratio of 0.019), whereby flagging this patient as an affected in the 2 nd percentile. Similar ratio values for the older control range were about 0.339 and about 0.021 5 for ax-glucosidase/ saposin C and a-glucosidase/ LAMP-I respectively. [0097] The multiplex data generated for Pompe patients was used to produce a ratio of -glucosidase to Lamp-1, and this ratio could distinguish 3 / 3 Pompe plasma samples and 9 / 9 Pompe blood spot samples from the corresponding plasma and blood spot samples from non-LSD patients. Similarly, the MPS I multiplex ratio data for a-iduronidase to LAMP-1 nd 10 was below the 2 percentile cut-off for 16/17 plasmas and 4/4 blood spots. As mentioned previously the one rogue MPS I plasma that does not fit the pattern, but still have been flagged as suspicious due to the very high a-iduronidase levels. [0098] Although not wanting to be bound by theory, the specific example of a 4-plex assay supports the invention that a multi-plex assay combined with protein profiling of two or 15 more lysosomal proteins improves the detection of MPS I and Pompe affected individuals in both plasma and blood spots. Determination of protein profiles that look at two, three, four or more than four-protein concentrations or corresponding ratios give even more discriminating power to the LSD multiplex assay. One aspect of this invention allows the ratios of LAMP-1 and saposin C to be used as markers to normalize the population for the lysosomal content of 20 the patient sample. For such disorders, these proteins profiles provide additional discriminatory power by showing an increase in concentration relative to the non-disease state. Multiplex technology improves the detection rate for most LSD and has an application in newborn screening programs for these diseases. [0099] As shown in the above examples of the multiplex concept combined with the 25 protein profile/fingerprint concept, there are many ways the profile can be analyzed. Levels of proteins, ratios of proteins and discriminate analysis have been described, but other examples could include the use of neural networks. Therefore, it will be readily apparent to one skilled in the art that various substitutions and modifications may be made in the invention disclosed herein without departing from the scope and spirit of the invention.

WO 2004/088322 PCT/AU2004/000403 32 EXAMPLE 4 [0100] 7-plex Lysosomal Protein Profile Assay. Protein markers for several LSD disorders are shown in Figure 20. A 7-plex assay for target antigens LAMP-1, saposin C, a 5 iduronidase, a-glucosidase, a-galactosidase, P-glucosidase and N-acetylgalactosamine-4 sulphatase was developed using the microsphere technology based upon Luminex LABMAPTM technology. [0101] Specific Target Capture Microspheres and Target Reporter Antibodies. Specific target capture microspheres and target reporter antibodies were produced using 10 antibodies directed against the seven specific target proteins (e.g. LAMP-1, saposin C, a iduronidase, a-glucosidase, a-galactosidase, P-glucosidase and N-acetylgalactosamine-4 sulphatase), and the coupling method as outlined above in Example 3. Briefly, the capture antibodies for LAMP-1, saposin C, a-iduronidase, a-glucosidase, oa-galactosidase, glucosidase and N-acetylgalactosamine-4-sulphatase were coupled to microsphere beads by 15 a 2-step carbodiimide reaction according to manufacturers instructions (Bio-Rad, Amine coupling kit 171-406001). Reporter antibodies were biotinylated according to manufacturers instructions (Molecular Probes, FluroReporter Biotin-XX protein labelling kit F-2610). The recombinant form of each protein were generated and used as standards. The dried blood spots that were collected from newborns, children and adults and used.,in this study were 20 samples submitted to the National Referral Laboratory and Neonatal Screening Laboratory Women's and Children's Hospital. Additional samples were collected from within the Lysosomal Disease Research Unit. Figure 21 shows the antibodies and bead regions used for the 7-plex assay. [0102] Sample Preparation and Method for Multiplexed Assays (7-plex). A 3mm 25 dried blood spots were pre-eluted in 130 1 of filtered (0.2jim) PBS containing 0.5% BSA (Sigma A-9647), 0.05% y-globulin (Sigma G-7516) and 0.05% Tween 20, pH7.2, (assay buffer) for 1 hour at room temperature with shaking, followed by 16 h at 4'C in 96 well, low protein binding plates (Greiner 655101). The blood spots were incubated a further 1 hour at room temperature with shaking and 100pl of each eluted sample was used for the multiplex 30 assay. Bead assays were performed in 96 well filtration plates (Millipore MAB VNS 1250) WO 2004/088322 PCT/AU2004/000403 33 sealed and protected from light. Samples and standards were performed in duplicate except for the newborn blood spots where only single samples were used. [0103] Antibody coated beads (5,000/well) for each individual assay were mixed and placed into pre-wetted filtration plates and the supernatant removed by vacuum. Diluted pre 5 mixed standards or samples were added to the beads followed by the 7 pre-mixed biotinylated reporter antibodies. The plates were incubated for 1 hour at room temperature with shaking, then placed at 4*C overnight. After a further 1 hour incubation at room temperature with shaking, the plates were washed 3 times with filtered (0.21Am) PBS containing 0.05% Tween 20, pH 7.2 (wash buffer) under vacuum. Streptavidin conjugated to phycoerythrin (Molecular 10 Probes S-866) was diluted in assay buffer (1.5 ug/mL) and added to the wells (100 gl/well), then the plates were incubated at room temperature with shaking for 10 minutes. The plates were then read on the Bio-Plex suspension array system (Bio-Rad) using version 3.0 software and counting 100 beads/region. [0104] Results for Multiplexed Assays (7-plex). Control blood spots from 12 adult 15 and 28 newborn control individuals were assayed for the 7 lysosomal proteins; LAMP-1, saposin C, a-iduronidase, a-glucosidase, ax-galactosidase, p-glucosidase and N acetylgalactosamine-4-sulphatase. Figure 22 shows the calibration curves for each of the protein assays. Figure 23 shows the individual and average adult control protein values in the 7 plex assay obtained for each sample with the standard deviation, minimum and maximum of 20 each group. Figure 24 shows the individual and average newborn protein values in the 7 plex assay for each sample with the standard deviation, minimum and maximum of each group. Standard deviation, minimum and maximum are also presented as multiples of the mean (MOM). Comparison of the standard deviation, minimum and maximum MOM values for the adult and newborn groups show that the newborn group has a wider range than the adult 25 group. [0105] Figure 25 shows the Pearson correlation coefficient between each pair of target protein analytes. With the exception of a-iduronidase, the target antigens showed a significant correlation to the other target antigens.

WO 2004/088322 PCT/AU2004/000403 34 [0106] Dried blood spot samples from 16 LSD affected individuals representing 5 different disorders were also analysed with the 7-plex protein profile. The results of these analyses are shown in Figure 26 (compared to the adult control group) and Figure 27 (compared to the newborn control group). The LSD patients were clearly distinguished from 5 the control groups. EXAMPLE 5 [0107] Multiplex Method to Screen the Newborn Population for Major LSD's. A ,general multiplex neonatal screening strategy for LSD is illustrated in Figure 28. A neonatal screening strategy for LSD's can be customized depending upon the geographic region and 10 LSD prevalence. For example, the following 14-Plex is an example of an assay suitable for use in North America and Europe. Twelve specific LSDs were chosen because of their relatively high prevalence in North America and Europe, together with the availability of effective therapies that would benefit from early diagnosis. A multiplex assay for the following 14 target proteins can test for the associated LSD that is shown in parentheses: 15 LAMP-1 (generic LSD), saposin C (generic LSD), a-glucosidase (Pompe), a-galactosidase A (Fabry), glucocerebrosidase or p-glucosidase (Gaucher), a-iduronidase (MPS I), iduronate-2 sulphatase (MPS II), heparan-N-sulphatase (MPS HIA), a-N-acetylglucosaminidase (MPS 111B), galactose-6-sulphatase (MPS IVA), P-galactosidase or galactocerebrosidase (Krabbe), galactose-3-sulphatase (MLD), sphingomyelinase (Niemann-Pick A/B) and N 20 acetylgalactosamine-4-sulphatase (MIPS VI). [0108] The protein profiling multiplex technology enables combinations of LSD target antigens to be modified as LSD treatment methods improve, as new LSD are identified, or screening needs change in different geographic areas. Antibodies to each of the 14 LSD target antigens are needed for this 14-plex assay. 25 [0109] The present invention improves the accuracy and detection of each of the LSD's in a single multiplex assay. The target antigens LAMP-1 and saposin C are used as markers to normalize the population for the lysosomal content of the patient sample. For some disorders, these proteins may provide additional discriminatory power by showing an increase in concentration relative to the non-disease state. By calculating the ratio of these WO 2004/088322 PCT/AU2004/000403 35 proteins to the individual proteins deficient in each LSD, greater discriminatory power can be attained. This concept can be extended beyond the calculation of ratios of individual proteins to the determination of protein profiles that encompasses many different target antigen protein concentrations for a given sample. The use of discriminate analysis or other statistical 5 methods can provide improved discrimination between control and affected populations. [0110] Protein profiling will improve the sensitivity and specificity of determining an LSD, wherein false negatives can be optimized to a sensitivity of 0-20% for most LSD's and false positives can be predicted between 0.1% and 0.01%. Additionally, confirmation assays can be performed on all positive assays prior to recalling the patient. Confirmation testing 10 for LSD type following Multiplex protein profiling can be completed by methods such as specific enzyme analysis, substrate storage analysis, or genotyping. Enzyme analysis comprises immune capture assay for specific lysosomal enzymes that are performed on a second blood spot. The substrate storage analysis comprises oligosaccharide and glycolipid analysis performed on second and third blood spots. Genotyping from dried blood spots 15 comprises screening for common mutations where appropriate on a further blood spots. [0111] It is understood that proteins characteristic of other LSD types can be replaceed, or added to the 14 target antigen lysosomal proteins listed above and that such modifications may depend on the frequency of individual LSD's for particular geographic regions. For example, the relative prevalence of individual LSD's is different in North 20 America, Japan and China. It is also understood that other biomolecules can represent the specific LSD target antigens or target molecules, such as antibodies, DNA sequences or RNA sequences or protein activities may be used or measured for the purposes multiplexing and profiling of target biomolecules this invention. EXAMPLE 6 25 [0112] Developing a Multiplex Profiles for a LSD. In one embodiment of the invention a series of at least two lysosomal proteins (e.g. a-glucosidase, f-glucosidase, a galactosidase, a-iduronidase, iduronate-2-sulphatase and N-acetylgalactosamine-4-sulphatase, etc.) are multiplexed. Samples from a control population (n > 100) are analyzed with the multiplexed assay to determine the normal range for each of the analytes. Each analyte is WO 2004/088322 PCT/AU2004/000403 36 normalized to general lysosomal markers (e.g. LAMP-1 and saposin C) in addition to the other specific markers to produce a series of ratios, or a fingerprint table. These ratios are then used to provide a profile of the control population. Samples from .a target population (Pompe, Gaucher, and other LSD affected individuals) (n > 20) are analyzed and the results 5 normalized as described in previous examples. The specific ratios that best differentiate the control and target populations are then utilized develop a specific profile/fingerprint of the LSD disease state. EXAMPLE 7 [0113] Multiplex Profiles for Specific a LSD. In one embodiment of the invention a 10 series of at least two lysosomal proteins (e.g. a-glucosidase, 6-glucosidase, a-galactosidase, a-iduronidase, iduronate-2-sulphatase and N-acetylgalactosamine-4-sulphatase, etc.) are multiplexed and utilized as a specific disease diagnostic (e.g. Pompe, Gaucher, Fabry, MPS, Niemann-Pick, Krabbe, etc.). Samples from a control population of patients are analyzed with the specific LSD multiplexed assay to determine the normal range for each of the 15 analytes in the control population. Each analyte is normalized to the general lysosomal markers (e.g. LAMP-1 and saposin C) in addition to the other specific markers to produce a series of ratios. These ratios are then used to provide a profile of the control population. Samples from a target population of patients (e.g. Pompe, Gaucher, Fabry, MPS, Niemann Pick, Krabbe, etc.) are also analyzed to determine the diseased state reference range of each 20 analyte in a target disease population. The level of each analyte in the target population is identified as being elevated, decreased or unchanged, relative to the control population. This provides a protein profile or fingerprint for the target disease state. Target populations representing each LSD of interest can be analyzed by this method and specific profiles/fingerprints can be obtained. Samples from patients with an unknown LSD clinical 25 status are then analyzed and the resulting patterns compared with the available target protein profiles to identify the specific LSD disease. EXAMPLE 8 [0114] Multiplex Profiles for LSD Disease Progression and Therapy Monitoring. At least two lysosomal proteins (e.g. LAMP-1, saposin C, a-glucosidase, 0-glucosidase, a- WO 2004/088322 PCT/AU2004/000403 37 galactosidase, a-iduronidase, iduronate-2-sulphatase and N-acetylgalactosamine-4-sulphatase, etc) are multiplexed. Samples from a control population are analyzed with the multiplexed assay to determine the normal range for each of the analytes. Samples from a population of individuals affected with a specific LSD (e.g. Pompe, Gaucher, Fabry, MPS, Niemann-Pick, 5 Krabbe, etc.) in are also analyzed to determine the reference range of each analyte in the LSD affected population. The two sets of data are used as a training data set to perform discriminate analysis. This discriminate analysis will allow the identification of the LSD disease affected individuals from the control population and classification for each LSD patient that is correlated to the disease severity (phenotype), or provide a prediction of 10 phenotype (disease progression) in asymptomatic patients. Samples taken from a LSD affected individual at different times during the course of therapy are analysed. The discriminate function is used to determine the degree of normalisation of the protein profile for that individual (i.e how close does it approach the control profile) and thereby monitor the efficacy of therapy. 15 EXAMPLE 9 [0115] Multiplex Profiles for Pompe. In one embodiment of the invention a series of at least two lysosomal proteins (e.g. a-glucosidase, P-glucosidase, aX-galactosidase, CC iduronidase, iduronate-2-sulphatase and N-acetylgalactosamine-4-sulphatase, etc.) are multiplexed and utilized as a specific disease diagnostic for Pompe disease. Samples from a 20 control population (n > 100) of patients are analyzed with the specific LSD multiplexed assay to determine the normal range for each of the analytes in the control population. Each analyte is normalized to the general lysosomal markers (e.g. LAMP-1 and saposin C) in addition to the other specific markers to produce a series of ratios. These ratios are then used to provide a profile of the control population. Samples from a target population of patients Pompe (n > 25 20) are also analyzed to determine the LSD state reference range of each analyte in Pompe disease population. The level of each analyte in the Pompe population is identified as being elevated, decreased or unchanged, relative to the control population. This provides a protein profile or fingerprint for the Pompe disease state. Target populations representing each level of Pompe severity of interest can be analyzed by this method and specific profiles/fingerprints 30 can be obtained. Samples from patients with an unknown LSD clinical status are then analyzed and the resulting patterns compared with the available target protein profiles to WO 2004/088322 PCT/AU2004/000403 38 identify the specific Pompe LSD disease. Additionally, the discriminate function can be used determine the degree of normalization of the protein profile for that individual (i.e. how close do the values approach the control profile) and thereby monitor the efficacy of a therapy. 5 EXAMPLE 10 [0116] Multiplex Newborn Screening. In one embodiment of the invention a series of lysosomal proteins (LAMP-1, saposin C, ax-glucosidase, P-glucosidase, a-galactosidase, a iduronidase, iduronate-2-sulphatase and N-acetylgalactosamine-4-sulphatase) are multiplexed. Samples (e.g., dried blood spots) from newborns in a given population are analyzed for a 10 specific LSD (e.g. none, Pompe, Gaucher, Fabry, MPS, Niemann-Pick, Krabbe, etc.) based on protein profiles/fingerprints of discriminate functions as described in Examples 5 - 9 above. The newborns are then assigned a probability of being affected by a LSD, wherein further testing may be required for newborns verification. EXAMPLE 11 15 [0117] Multiplex and Cancer. At least two lysosomal proteins (e.g. LAMP-1, saposin C, a-glucosidase, P-glucosidase, a-galactosidase, c-iduronidase, iduronate-2 sulphatase and N-acetylgalactosamine-4-sulphatase, etc) or cancer antigens are multiplexed. Samples from a control population are analyzed with the multiplexed assay to determine the normal range for each of the analytes. Samples from a target population (e.g. cancer affected 20 individuals) are also analyzed to determine the reference range of each analyte in this population. The two sets of data are used as a training set to perform discriminate analysis and identify a discriminate function that will enable the separation of the cancer affected individuals from the control population. The discriminate function is then used to identify patients having an unknown protein profile consistent with the particular cancer under 25 investigation. This embodiment thereby provides early identification of the cancer. [0118] Multiplex LSD protein profiling provides solutions to many issues relating to newborn screening assays. For example, multiplex LSD protein profiling provides sensitivity and specificity required to diagnose a specific selection of LSD disorders to be screened, 39 wherein additional lysosomal proteins can be added if needed. Multiplex LSD protein profiling also provides a platform technology to undertake screening for other LSD populations (e.g. Renal/cardiac clinics for Fabry disease; accociation of Fabry disease w/ end-stage renal failure, and association of Fabry disease w/idiopathic cardiomyopathy, muscle fatigue/soreness for adult Pompe disease, and 5 altered lysosomal function and protein levels in some types of cancers). Multiplex LSD protein profiling is also flexable to incorporate non-lysosomal protein markers (e.g. thyroid stimulating hormone, immunoreactive trypsin and others.) [0119] This invention comprises lysosomal protein profiling for LSD, which encompasses the use of protein marker ratios using existing LSD target markers that are increased with LSD, and the 0 use additional LSD target markers that are decreased with LSD. Protein profiling also utilizes a ratio of the LSD target markers to improve discrimination. Some LSD markers can be used to correct for lysosome/leukocyte levels. Additionally ratio specific markers (e.g. LAMP-I) can be utilized to correct for different lysosomal content and other ratio markers can be utilized to correct for white cell content (e.g. CD45). Protein profiles incorporate different proteins markers that are measured to 5 improve discrimination. Although Multiplex bead technology has been used as a specific example, other methods of multiple LSD target protein measurements can be utilized to perform protein profiling. Such methods do not deviate from the spirit and scope of the claimed invention. 101201 Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or 0 group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. 10121] All publications mentioned in this specification are herein incorporated by reference. Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is ?5 not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or elsewhere before the priority date of each claim of this application. [0122] It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing 0 from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

WO 2004/088322 PCT/AU2004/000403 40 REFERENCES CITED The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. 5 U.S. PATENT DOCUMENTS United States Patent 6,449,562 ("the '562 Patent") entitled "Multiplexed Analysis of Clinical Specimens Apparatus and Method," having Chandler et al. listed as inventors was issued on September 10, 2002. United States Patent 6,524,793 ("the '793 Patent") entitled "Multiplexed Analysis of 10 Clinical Specimens Apparatus and Method," having Chandler et al. listed as inventors, was issued on February 25, 2003. United States Patent Application Serial No. 09/956,857 ("the '857 Application") entitled "Multiple Reporter Read-out for Bioassays" was published on March 20,2003. 15 PCT Application AU03/00731 entitled "identification of Oligosaccharides and their Use in the Diagnosis and Evaluation of Mucopolysaccharidoses and Other Related Disorders," having Hopwood et al., listed as inventors, filed on June 13,2003 Other Publications 20 Carlsson, S.R., M. Fukuda, Structure of human lysosomal membrane glycoprotein 1, Assignment of disulfide bonds and visualization of its domain arrangement., J. Biol. Chem. 264:20526-20531 (1989). Fransen, J.A., L.A. Ginsel, P.H. Cambier, J. Klumperman, R.P. Oude Elferink, J.M. Tager, Immunocytochemical demonstration of the lysosomal enzyme alpha-glucosidase in 25 the brush border of human intestinal epithelial cells, Eur J Cell Biol 47:72-80 (1988). Harlow, E., D. Lane, Antibodies, A laboratory manual, Cold Spring Harbor Laboratory (1988). Hua, C.T. et al., Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders, Clin. Chem. 44(10): 2094-2102 (1988). 30 Isbrandt, D., G. Arlt, D.A. Brooks, J.J. Hopwood, K. von Figura, and C. Peters, Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Six unique arylsulfatase B gene alleles causing variable disease phenotypes, Am J Hum Genet 54(3): 454-63 (1994). Meikle et al., Prevalence of lysosomal storage disorders, JAMA 281: 249-254 (1999).

WO 2004/088322 PCT/AU2004/000403 41 Neufeld, E.F. and J. Muenzer, The mucopolysaccharidoses, The Metabolic & Molecular Basis of Inherited Disease, 7 th Edition., pp. 2465-2494 (1995). Umapathysivam, K., J.J. Hopwood, P.J. Meikle, Determination of acid alpha-glucosidase activity in blood spots as a diagnosis for Pompe Disease, Clin. Chem. 47(8): 1378 5 1383 (2001). Zola, H., D. Brooks, Techniques for the Production and Characterization of Monoclonal Hybridoma Antibodies, Monoclonal Hybridoma Antibodies: Techniques and Applications (1982).

Claims

1. A composition used for diagnosing a lysosomal storage disorder ("LSD") comprising: a capture antibody conjugated to a microsphere; and the microsphere having at least a first fluorophore and a second fluorophore wherein, the capture antibody is capable of binding a target antigen and characterized in that the target antigen comprises LAMP-], saposin C, a-glucosidase, a-galactosidase, glucocerebrosidase, P-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N-acetylglucosaminidase, galactose-6 sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase.

2. The composition of claim 1, further comprising a detection antibody, wherein the detection antibody is capable of binding the target antigen, but is different from the capture antibody; and the detection antibody is conjugated to a detection label.

3. The composition of claim I or 2, wherein the target antigen is a-iduronidase, a-glucosidase, a-galactosidase, p-glucosidase, N-acetylgalactosamine-4-sulphatase, saposin C, or LAMP-I.

4. The composition of any one of the preceding claims, wherein the target antigen is a-iduronidase, a-glucosidase, LAMP-I or saposin C.

5. The composition of any one of the preceding claims, wherein the first fluorophore is spectrally distinct from the second fluorophore. 5

6. The composition of any one of the preceding claims, wherein the microsphere has a diameter of about 5gm.

7. The composition of any one preceding claim, wherein the LSD is Fabry; Mucopolysaccharidosis type I ("MPS I"); Mucopolysaccharidosis type II ("MPS-II"); 0 Mucopolysaccharidosis type III ("MPS-III"); Mucopolysaccharidosis type IV ("MPS-IV"); or Glycogen storage disease II ("Pompe").

8. The composition of any one of claims I to 6, wherein the LSD is Gaucher disease types 1/11/III; Cystinosis; Mucopolysaccharidosis type VI; Mucopolysaccharidosis type IVA; Niemann-Pick 5 disease types A/B; Metachromatic leucodystrophy; Mucopolysaccharidosis type IIIA; Mucopolysaccharidosis type 11113; Mucopolysaccharidosis type III; Mucopolysaccharidosis type IIID; Mucopolysaccharidosis type VII; Mucopolysaccharidosis type IVB; Niemann-Pick disease type 43 Cl; Niemann-Pick disease type C2; Cholesterol ester storage disease; Aspartylglucosaminuria; GMI Gangliosidosis types 1/11/; GM2-Gangliosidosis type 1; GM2-Gangliosidosis type II; GM2 Gangliosidosis; Farber Lipogranulomatosis; Fucosidosis; Galactosialidosis types 1/Il; ct-Mannosidosis types I/II; p-Mannosidosis; Mucolipidosis type I; Mucolipidosis types 11 / Ill; Mucolipidosis type IIIC; Mucolipidosis type IV; Multiple sulphatase deficiency; Neuronal Ceroid Lipofuscinosis, CLN ; Neuronal Ceroid Lipofuscinosis, CLN2; Neuronal Ceroid Lipofuscinosis, CLN3 ; Neuronal Ceroid Lipofuscinosis, CLN5; Neuronal Ceroid Lipofuscinosis, CLN8; Pycnodysostosis; or Sialic acid storage disease.

9. A protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: (a) determining a target quantity of a-iduronidase or a-glucosidase from a target biological sample of the target animal; (b) determining a target quantity of either LAMP-I or saposin C from the target biological sample of the target animal; (c) assigning an adjusted target quantity by calculating a target proportion between the target quantity of a-iduronidase or a-glucosidase and the target quantity of either LAMP-I or saposin C; (d) obtaining a reference quantity of a-iduronidase or ct-glucosidase from a reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (e) obtaining a reference quantity of either LAMP-I or saposin C from the reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; 5 (f) assigning an adjusted reference quantity by calculating a reference proportion between the reference quantity of a-iduronidase or a-glucosidase and the reference quantity of either LAMP-I or saposin C; (g) determining a deviation of the adjusted target quantity compared to the adjusted reference quantity; and 0 the determination of the target quantity of a-iduronidase or a-glucosidase, the reference quantity of a-iduronidase or ca-glucosidase, the target quantity of either LAMP-1 or saposin C, and the reference quantity of either LAMP-i or saposin C are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second fluorophore, wherein the capture 5 antibody is capable of binding to a-iduronidase or a-glucosidase or LAMP-1 or saposin C; and a significant deviation of the adjusted target quantity compared to the adjusted 44 reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U(MWU) test.

10. The protein profiling method of claim 9, wherein the target biological sample and the reference biological sample is selected from a cellular extract, blood, plasma or urine.

11. The protein profiling method of claim 9 or 10, wherein the LSD is Mucopolysaccharidosis type I ("MPS I"); Mucopolysaccharidosis type II ("MPS-II"); Mucopolysaccharidosis type III ("MPS III"); Glycogen storage disease II ("Pompe"); gangliosidosis; or Gaucher disease.

12. A protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: (a) determining target quantities of a-iduronidase, a-glucosidase, ct-galactosidase, p-glucosidase, and N-acetylgalactosamine-4-sulphatase, from a target biological sample of the target animal; (b) determining a target quantity of either LAMP-I or saposin C from the target biological sample of the target animal; (c) assigning a set of adjusted target quantities by calculating a target proportion between the target quantities of a-iduronidase, a-glucosidase, a-galactosidase, p-glucosidase, and N-acetylgalactosamine-4-sulphatase, and the target quantity of either LAMP-I or saposin C; (d) obtaining reference quantities of a-iduronidase, a-glucosidase, a-galactosidase, p-glucosidase, and N-acetylgalactosamine-4-sulphatase, from a reference biological 5 sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (e) obtaining a reference quantity of either LAMP-I or saposin C from the reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; 0 (f) assigning a set of adjusted reference quantities by calculating a reference proportion between the reference quantities of a-iduronidase, a-glucosidase, a-galactosidase, P-glucosidase, and N-acetylgalactosamine-4-sulphatase, and the reference quantity of either LAMP-1 or saposin C; and (g) determining a deviation of the set of adjusted target quantities to the set of adjusted 5 reference quantities; 45 wherein, the determination the target quantities of a-iduronidase, a-glucosidase, a-galactosidase, 0-glucosidase, and N-acetylgalactosamine-4-sulphatase, the target quantity of either LAMP-I or saposin C, the reference quantities of a-iduronidase, a-glucosidase, a-galactosidase, p-glucosidase, and N-acetylgalactosam'iine-4 sulphatase, and the reference quantity of either LAMP-I or saposin C are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second fluorophore, wherein the capture antibody is capable of binding to a-iduronidase, a-glucosidase, a-galactosidase, p-glucosidase, N-acetylgalactosamine-4-sulphatase, LAMP-1 or saposin C; and a significant deviation of any of the adjusted target quantities compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U(MWU) test.

13. The protein profiling method of claim 12, wherein the target biological sample and the reference biological sample is selected from a cellular extract, blood, plasma or urine.

14. The protein profiling method of claim 12, wherein the LSD is Fabry; Mucopolysaccharidosis type I ("MPS I"); Mucopolysaccharidosis type II ("MPS-II"); Mucopolysaccharidosis type VI ("MPS VI"); Mucolipidosis II/II ("ML II/II"); Mucolipidosis II/III ("ML II/Ill"); or Glycogen storage disease II ("Pompe").

15. A protein profiling method for diagnosing a preclinical status, or a clinical status, and 5 determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: (a) determining target quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, P-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, 0 from a target biological sample of the target animal; (b) determining a target quantity of either LAMP-I or saposin C from the target biological sample of the target animal; (c) assigning a set of adjusted target quantities by calculating a target proportion between the target quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, 5 p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, 46 N-acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3 -sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, and the target quantity of either LAMP-I or saposin C; (d) obtaining reference quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N-acetylglucosaminidase, galactose-6-sulphatase, $-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, from a reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (e) obtaining a reference quantity of either LAMP-I or saposin C from the reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (f) assigning a set of adjusted reference quantities by calculating a reference proportion between the reference quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N sulphatase, N-acetylglucosaminidase, galactose-6-sulphatase, p-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, and the reference quantity of either LAMP-I or saposin C; and (g) determining a deviation of the set of adjusted target quantities to the set of adjusted reference quantities; wherein, 5 the determination the target quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N sulphatase, N-acetylglucosaminidase, galactose-6-sulphatase, P-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, the target quantity of either LAMP-I or saposin 0 C, the reference quantities of a-glucosidase, a-galactosidase, glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N-sulphatase, N-acetylglucosaminidase, galactose-6-sulphatase, P-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, and N-acetylgalactosamine-4-sulphatase, and the reference quantity of either LAMP-1 or 5 saposin C, are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second fluorophore, wherein the 47 capture antibody is capable of binding a-glucosidase, a-galactosidase, glucocerebrosidase, p-glucosidase, a-iduronidase, iduronate-2-sulphatase, heparin-N sulphatase, N-acetylglucosaminidase, galactose-6-sulphatase, P-galactosidase, galactocerebrosidase, galactose-3-sulphatase, spingomyelinase, N-acetylgalactosamine-4-sulphatase, LAMP-I or saposin C; and a significant deviation of any of the adjusted target quantities compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U(MWU) test.

16. The protein profiling method of claim 15, wherein the target biological sample and the reference biological sample is selected from a cellular extract, blood, plasma or urine.

17. The protein profiling method of claim 15, wherein the LSD is Pompe, Fabry, Gaucher, MPS 1, MPS II, MPS lIlA, MPS IIIB, MPS IVA, Krabbe, mucolipidosis disease (MLD), Niemann-Pick A/B or MPS VI.

18. A protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: (a) determining at least a first target biomolecule quantity from a target biological sample of the target animal; (b) determining at least a second target biomolecule quantity from the target biological sample of the target animal; (c) assigning an adjusted target quantity by calculating a target proportion between the 5 first target biomolecule quantity and the second target biomolecule quantity; (d) obtaining a first reference biomolecule quantity of a reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (e) obtaining a second reference biomolecule quantity of a reference biological sample 0 from a reference animal, or group of reference animals, having a known LSD pre clinical or clinical status; (f) assigning an adjusted reference quantity by calculating a reference proportion between the reference first reference biomolecule quantity and the second reference biomolecule quantity; 48 (g) determining a deviation of the adjusted target quantity compared to the adjusted reference quantity; wherein, the first target biomolecule is the same or equivalent to the first reference biomolecule; and the second target biomolecule and the second reference biomolecule are either LAMP-I or saposin C; the determination of the first target biomolecule quantity and the second target biomolecule quantity are performed using a capture antibody conjugated to a microsphere, the microsphere having at least a first fluorophore and a second fluorophore, wherein the capture antibody is capable of binding to the first target biomolecule or the second target biomolecule; and a significant deviation of the adjusted target quantity compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U(MWU) test; and wherein the first target biomolecule and the first reference biomolecule are each a-glucosidase and the LSD is Pompe; or the first target biomolecule and the first reference biomolecule are each a-galactosidase A, and the LSD is Fabry; or the first target biomolecule and the first reference biomolecule are each glucocerebriosidase or p-glucosidase, and the LSD is Gaucher; or the first target biomolecule and the first reference biomolecule are each a-iduronidase and the LSD is MPS I; or 5 the first target biomolecule and the first reference biomolecule are each iduronate-2 sulphatase and the LSD is MPS II; or the first target biomolecule and the first reference biomolecule are each heparin-N sulphatase and the LSD is MPS IIIA; or the first target biomolecule and the first reference biomolecule are each a-N 0 acetylglucosaminidase and the LSD is MPS 1I1B; or the first target biomolecule and the first reference biomolecule are each galactose-6 sulphatase and the LSD is MLD; or the first target biomolecule and the first reference biomolecule are each 49 sphingomyelinase and the LSD is Niemann-Pick; or the first target biomolecule and the first reference biomolecule are each N-acetylgalactosamine-4-sulphatase and the LSD is MPS IV.

19. A protein profiling method for diagnosing a preclinical status, or a clinical status, and determining therapy of a lysosomal storage disorder ("LSD") in a target animal comprising: (a) determining a target quantity of a-iduronidase or a-glucosidase from a target biological sample of the target animal; (b) determining a target quantity of either LAMP-I or saposin C from the target biological sample of the target animal; (c) assigning an adjusted target quantity by calculating a target proportion between the target quantity of a-iduronidase or a-glucosidase and the target quantity of either LAMP-I or saposin C; (d) determining a second target quantity of a-iduronidase or a-glucosidase from a second target biological sample of the target animal; (e) determining a second target quantity of either LAMP-I or saposin C from the second target biological sample of the target animal; (f) assigning a second adjusted target quantity by calculating a second target proportion between the second target quantity of a-iduronidase or a-glucosidase and the second target quantity of either LAMP-I or saposin C; (g) obtaining a reference quantity of a-iduronidase or a-glucosidase from a reference biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (h) obtaining a reference quantity of either LAMP-I or saposin C from the reference 5 biological sample from a reference animal, or group of reference animals, having a known LSD pre-clinical or clinical status; (i) assigning an adjusted reference quantity by calculating a reference proportion between the reference quantity of a-iduronidase or a-glucosidase and the reference quantity of either LAMP-I or saposin C; 0 (j) determining (i) a deviation of the adjusted target quantity compared to the adjusted reference quantity; (ii) a second deviation of the second adjusted target quantity compared to the adjusted reference quantity; and the determination of the target quantity of a-iduronidase or a-glucosidase, the reference quantity of a-iduronidase or a-glucosidase, the target quantity of either 5 LAMP-I or saposin C, and the reference quantity of either LAMP-I or saposin C are performed using a capture antibody conjugated to a microsphere, the microsphere 50 having at least a first fluorophore and a second fluorophore, wherein the capture antibody is capable of binding to a-iduronidase or a-glucosidase or LAMP-I or saposin C; and a significant deviation of the adjusted target quantity compared to the adjusted reference quantity is a pre-clinical or clinical indication of a specific LSD, wherein a deviation is significant if the absolute value of the deviation is greater than or equal to a standard deviation calculated by a Mann-Whitney U(MWU) test; and the second target biological sample is obtained at a different time point than the target biological sample and a magnitude of divergence between the deviation and the second deviation determines whether the LSD therapy will be administered, monitored, or modified.